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Pancreatic cancer is one of the most deadly of all types of cancer with an overall 5-year 
survival rate of less than 9%. Cancer cells in the pancreatic tumor are heterogeneous, and it is 
poorly understood which population is most responsible for the cancer initiation, progression, and 
metastasis. Recent studies provide evidence for the existence of highly tumorigenic and 
metastatic cells within a heterogeneous tumor known as the cancer stem cells. Studies also 
provided ample evidence for the existence of distinct types of cancer stem cell populations in a 
heterogeneous tumor with type-specific genotypic, phenotypic and functional characteristics. 
However, it is not clear how cancer stem cells are induced, and how these cells are involved in 
the metastasis process. Several external factors such as cigarette smoking and alcohol 
consumption have been shown to induce cancer stem cells in lung and breast cancers. Cigarette 
smoking is also associated with 30% of pancreatic cancer cases. The association of smoking with 
cancer stemness is also well appreciated in lung cancer and other cancers. Based on these 
studies, we aimed to investigate whether and how cigarette smoke induces cancer stem cells in 
pancreatic cancer in the first part of my dissertation.   
In this dissertation, the first study of my work was to understand the mechanistic role of 
cigarette smoke on the induction of pancreatic cancer stem cells. For which we exposed KrasG12D 
and KrasG12D; Pdx1Cre mouse models to cigarette smoke for 20 weeks; and treated pancreatic 
normal and cancer cell lines with cigarette smoke extract for 80 days. Our results indicated that 
chronic exposure to cigarette smoke induces stemness in pancreatic normal and cancer cells. 
We demonstrated that cigarette smoke and its ingredients, NNN and NNK induce stemness by 
upregulating PAF1, a major stemness regulating factor through CHRNA7/ERK/AP1 signaling 
axis. Loss of PAF1 reduced the cigarette smoke-induced stemness suggesting that PAF1 
regulates smoking-mediated induction of pancreatic stemness/cancer stemness. We also proved 
that upon PAF1 induction, it interacts with PHF5A, a PAF1 complex stabilizing protein and 
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stemness factor to form PAF1-PHF5A complex, which is required for the activation of stemness 
genes. Overall, this first part of the study showed the mechanism of how stemness or cancer 
stemness is induced in response to cigarette smoking, one of the significant risk factor of 
pancreatic cancer.     
Our second goal primarily explores the metastatic function of cancer stem cells in 
pancreatic cancer. Previous studies have shown the existence of distinct cancer stem cell 
populations in a heterogeneous tumor. For instance, breast tumors consist of two distinct CSC 
populations such as ALDH+ and CD44+CD24-. The study also demonstrated that ALDH+ cells 
rely on oxidative phosphorylation for their energy needs, whereas CD44+CD24- population rely 
on glycolysis. Recent studies also proposed the propensity of a specific cancer cell with specific 
metabolic profile metastasizes to a specific organ. For instance, the liver has a high glycolytic 
environment, and a metastatic cell required to be highly glycolytic to overcome the glycolytic 
barrier in the liver. Based on these studies, we have hypothesized that distinct types of cancer 
stemness populations with type-specific stemness and metabolic profiles metastasize to a specific 
organ. Investigation of this hypothesis led to the identification of two distinct cancer stem cells 
populations in pancreatic cancer: ALDH+ or CD133+ population and drug-resistant (MDR1+ or 
ABCG2+) population. We also demonstrated that these distinct types of cancer stemness 
populations showed type specific metabolic profile: ALDH+ or CD133+ population were identified 
as oxidative, whereas drug-resistant population showed a Warburg effect. Altogether, our data 
provided evidence for the existence of distinct types of cancer stemness populations with type-
specific stemness and metabolic profiles. Currently, we are in the process of investigating the 
organ-specific metastasis of these distinct cancer stem cell populations using an orthotopic nude 
mice model. 
Overall, our findings demonstrate a precise mechanism of cancer stem cell induction. 
Besides, our investigation suggests the existence of distinct cancer stemness populations with 
specific metabolic, stemness and metastatic profiles. In conclusion, our work provides a solid 
foundation for the understanding of cancer stem cells in pancreatic cancer thereby opening new 
avenues for further research in developing cancer stem cell-targeted therapy for pancreatic 
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Cancer biology research over recent decades has given ample evidence for the existence of self-
renewing and drug-resistant populations within heterogeneous tumors, widely recognized 
as cancer stem cells (CSCs). However, a lack of clear understanding of the origin, existence, 
maintenance, and metastatic roles of CSCs limit efforts towards the development of CSC-targeted 
therapy. In this review, we describe novel avenues of current CSC biology. In addition to cell 
fusion and horizontal gene transfer, CSCs are originated by mutations in somatic or 
differentiated cancer cells, resulting in de-differentiation and reprogramming. Recent studies also 
provided evidence for the existence of distinct or heterogeneous CSC populations within a single 
heterogeneous tumor. Our analysis of the literature also opens the doors for a novel hypothesis 
that CSC populations with specific phenotypes, metabolic profiles, and clonogenic potential 
















Why does a tumor relapse after its initial remission? The quest for an answer to this question led 
in 1959 to the derivation of the term “tumor stem cells” [1]. Tumors comprise a heterogeneous 
cell population, with 0.1% to 0.8% of these tumor cells being cancer stem cells (CSCs) [2]. 
Research on CSCs was launched for the first time in 1994 when Lapidot and colleagues observed 
in primary human acute myeloid leukemia (AML) that a small subpopulation of cells, CD34+CD38-
, initiate tumor in severe combined immune deficient mice (SCID) [3]. In the light of this evidence, 
following studies from 1994 to date investigated for the presence of CSCs or tumor-initiating cells 
in various cancers and observed that a small population of drug-resistant, tumor-initiating, and 
stemness-activated CSCs are present in almost all cancer types. Lineage tracing experiments by 
three independent groups in 2012 further fueled recognition of the existence of CSCs [[4], [5], [6]]. 
1.1. The relevance of CSCs in cancer initiation 
CSCs differentiate into self-renewing cells and differentiated cells that make up the entire bulk of 
the tumor [7]. According to the CSC hypothesis, “stem cells,” by residing at the top of the cellular 
hierarchy in each tumor, can self-renew and give rise to heterogeneous cell populations within 
the tumor. Studies focusing on CSCs demonstrated that implantation of even a small number of 
CSCs could form tumors suggesting the significance of CSCs in cancer initiation [8]. 
This was further confirmed in a study by Driessens et al., wherein using genetic lineage tracing 
experiments it was demonstrated that a fraction of tumor cells and long term persisting stem-like 
cells have an increased proliferative potential and produce progeny that occupied a significant 
part of the tumor in squamous skin cancer [5]. Another study also demonstrates that Lgr5+ stem 
cells in intestinal adenomas produce the cells of entire adenoma by maintaining Lgr5+ stem cell 
population [6]. These studies suggest that CSCs are the primary culprits for the initiation and 
progression of cancers. 
Four aspects of CSC biology have been investigated in the literature, including origin, manifold 
existence, maintenance, and metastasis of CSCs (OMMM of CSCs) (Fig. 1). Current evidence 
suggests that cell fusion, horizontal gene transfer, and mutations drive cellular transformation and 
reprogramming into CSCs. Besides, metabolic shifts from glycolytic to oxidative phosphorylation, 
or vice versa, also induce cancer stemness [9]. 
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A challenge in understanding CSC biology is the lack of consensus about the markers of CSCs. 
Different studies propose varying markers for CSCs in different cancers. Emerging evidence 
suggests that tumors consist of heterogeneous CSC subtype populations, and each subtype of 
CSCs display a unique phenotype and unique clonogenic and metastatic potential. Our 
understanding of how these heterogeneous CSC subtype populations are maintained and 
contribute to the cancer biogenesis and aggressiveness after their generation also remains 
limited. 
Studies suggest that CSCs within tumors have the potential to migrate to specific organs 
[10,11]. Exosomes, small extracellular vesicles released by cells, carry cellular components to 
distant organs, thereby increasing cellular communications [12]. Recent studies have shown that 
the exosomes released by cancer cells within a primary tumor journey to distant organs and form 
a pre-metastatic niche [12,13]. However, it is not known which cell type in a heterogeneous 
primary tumor releases the exosomes with the capacity to form a pre-metastatic niche in distant 
organs. In this review, we discussed the concept of CSCs from its origin to metastasis and 
described the perspective about the role of CSCs in organ trophic metastasis. 
2. General features of cancer stem cells 
The CSC hypothesis emerged a decade ago; however, it is still unclear what makes these CSCs 
unique compared to normal cells, other non-cancerous stem cells, or cancer cells. Most cell 
signaling pathways and cell surface and intracellular markers are similar in a normal cell, stem 
cell, CSC, and cancer cells. For instance, bone marrow-derived mesenchymal stem cells express 
high levels of the CD90 cell surface marker [14]. However, the same marker has also been 
proposed as a CSC marker in primary high-grade gliomas and other cancers [15]. 
Similarly, CD44, an well-known CSC marker, is also highly expressed in normal endometrial cells 
and regulates the function of normal endometrium [16]. Here, we explore the features that could 
potentially derive CSCs. 
2.1. Recapitulation of embryonic signature in CSCs 
The most prominent and specific feature which can be observed in CSCs is the recapitulation of 
embryonic pluripotent networks and the overexpression of embryonic genes [17]. During 
development, TGF-β, FGFR/MAPK or Akt, Wnt, Notch, and sonic hedgehog pathways maintain 
self-renewal and pluripotency of embryonic stem cells (ESCs). These pathways ultimately 
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activate three major transcription factors: Oct3/4, SOX2, and Nanog. These factors activate ESC-
specific genes and maintain the stem cell state of ESCs by inhibiting differentiation genes. 
During embryo development and organ specification, pluripotent genes are inhibited, and 
differentiation genes are activated. Thus, in adult tissues, the expression levels of Oct3/4, SOX2, 
Nanog, and other ESC maintenance genes is very low [18, 19]. However, during the initiation and 
progression of cancers, these ESC genes and networks are activated. The aberrant expression 
of ESC genes and activation of stemness networks leads to the enrichment of CSCs, which initiate 
or aggravate tumor. 
2.2. Mutations distinguish CSCs from non-CSCs 
CSCs also differ from other non-CSC populations in that CSCs show mutations leading to the 
aberrant regulation of majority of the stemness and proliferation pathways. Even though the same 
signaling pathways are seen in CSCs and non-CSCs, their enhanced and aberrant activation 
distinguishes CSCs from non-CSCs. For instance, aberrant activation of the Wnt pathway has 
been shown to induce CSCs [20,21]. 
2.3. CSCs are quiescent 
CSCs also have another striking specific property; i.e., CSC quiescence. CSCs are a low-cycling 
quiescent cell population residing within the tumor. These low-cycling CSCs are responsible for 
the tumor aggressiveness and metastasis [22,23]. Resistance to chemotherapeutic drugs is 
another specific property of CSCs, and this resistance is usually conferred by ABCG2 and 
other drug resistance receptors [24]. 
3. Origin of cancer stem cells 
3.1. Cell fusion and stem cells 
CSCs originate through cell fusions (Fig. 2), wherein cells acquire extra properties through a 
process in which two cells fuse to form hybrids with a higher degree of aneuploidy [25]. The fusion 
of 5-fluorouracil- (5-FU) resistant cancer cells with methotrexate-resistant cancer cells produces 
aneuploidy hybrid cells, resistant not only to 5-FU and methotrexate but also to melphalan. Also, 
Rizvi and colleagues showed that the fusion of bone marrow-derived stem cells with intestinal 
tumor epithelial cells do not produce a resistant CSC population, nor do the new hybrid cells 
induce cancer [26]. However, polyploid giant cancer cells (PGCCs), which are aroused because 
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of cell fusion have been shown to display drug resistance and tumorigenic properties [27,28]. 
Overall, poor evidence from literature for the fusion-mediated CSC origin limits this model. 
3.2. Horizontal gene transfer 
Another mechanism that could potentially contribute to the origin of CSCs is horizontal gene 
transfer [29], which is usually an adaptation mechanism found in bacteria and fungi that use this 
mechanism to acquire resistance to antibiotics [30]. Horizontal transfer is a mechanism whereby 
DNA from donor cells is delivered into recipient cells, followed by insertion of donor DNA 
sequences into the host genome and expression of the inserted gene sequence. The expression 
of inserted gene sequence in the host helps the host cell to acquire resistance to antibiotics. 
In eukaryotic cells, the horizontal transfer occurs between an apoptotic cell (donor) and a recipient 
cell through endocytosis or phagocytosis. Apoptosis and consequent DNA fragmentation in 
a somatic cell are the results of mutations. The fragmented DNA is endocytosed by 
another somatic cell [31] or tumor cell [29], leading to the formation of cells with a more 
aggressive phenotype. This suggests that horizontal gene transfer might play an important role in 
the generation of resistant CSCs by the transfer of mutated genetic material from apoptotic bodies 
derived from therapy-sensitive cancer cells to somatic or other therapy-resistant cancer cells. 
However, a lack of experimental evidence has limited the reliability of this phenomenon. 
3.3. Mutations lead to the formation of CSCs 
Various conditions, such as radiation treatment, tissue injury, and exposure to toxins (from 
smoking and the like) induce mutations in certain genes, including p53 (tumor suppressor) and 
Kras [32]. Fujimori et al. have demonstrated that extracellular stress induces cancerous genes in 
differentiating embryonic stem cells (ESCs), producing CSC populations [33]. The harmful 
external signals can also deregulate or enhance certain signaling pathways in normal adult stem 
cells (ASCs) and can lead to the transformation of these ASCs into CSCs. For instance, arsenic 
has been shown to induce the transformation of normal prostate epithelial stem cells into CSCs 
[34]. Also, mutations in symmetrically dividing normal ASCs transform an ASC into a CSC. 
Furthermore, ASCs undergo continuous division for a long time, and this increases the chances 
of accumulating mutations that lead to the transformation of a normal ASC into CSC. On the other 
hand, mutations in oncogenes and tumor suppressor genes of mesenchymal stem cells (MSCs) 
induce the transformation of MSCs into CSCs, leading to the initiation and progression 
of sarcomas [35]. Conditional inactivation of p53, NF1, and Pten tumor suppressors in neural 
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stem/progenitor cells converted these cells into CSCs and initiated brain tumors [36]. A genome-
wide mutation pattern analysis in ASCs in the human small intestine, colon, and liver 
tissues showed that mutations accumulate steadily in these tissues at a rate of 40 mutations per 
year. The mutation spectra of genes associated with carcinogenesis are also like the mutation 
spectra of tissue-specific ASCs, suggesting that mutations in ASCs can induce carcinogenesis 
[37]. 
3.4. De-differentiation of non-CSCs into CSCs 
Another phenomenon responsible for the origin of CSCs is cellular de-differentiation. A 
differentiated cancer cell can de-differentiate into a CSC in response to various factors, including 
wounding, stress, and hypoxia, leading to cancer initiation and progression. A recent study 
showed that glioma cells could de-differentiate into glioma stem-like cells (GSCs) in response to 
stress and hypoxia-induced HIF1α signaling. Also, angiocrine factors such as nitric oxide (NO) 
have been shown to drive de-differentiation of glioma cells into GSCs [[38], [39], [40]]. Wounding 
also induces Gata6+ epidermal stem cells into stem-like cells, suggesting that wounding can also 
de-differentiate a differentiated cell into a stem cell [41]. Ionizing radiation also converted cancer 
cells into a stem-like phenotype, with increased metastasis [42]. By undergoing EMT, pancreatic 
ductal cells have been shown to acquire CSC phenotype through de-differentiation [43]. These 
studies collectively suggest de-differentiation as an important phenomenon involved in the 
generation of CSCs in various cancers. 
3.5. Metabolic reprogramming of CSCs 
Metabolic adaptation is central in cancer cells, especially regarding glycolysis. In glycolysis, 
glucose is broken down through a series of steps into pyruvate, producing two molecules 
of ATP per one molecule of glucose. In the presence of enough oxygen levels, pyruvate 
enters oxidative phosphorylation and produces 36 ATP molecules per one glucose molecule. 
Thus, oxidative phosphorylation is more efficient than glycolysis in generating ATP molecules. 
However, cancer cells, as hypothesized by Warburg, show increased glycolysis to produce ATP, 
even in the presence of oxygen, and it converts pyruvate into lactate to create a condition of 
fermentative metabolism that is highly conducive to the activity of cancer cells. If sufficient levels 
of glucose are available, aerobic glycolysis can generate more energy more rapidly than can 
oxidative phosphorylation [44]. 
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Otto Heinrich Warburg, a German physiologist, theorized that one of the most important causes 
of cancer is variation in metabolism. According to his theory, cancer cells generate energy through 
the anaerobic breakdown of glucose even in the presence of oxygen. Hence, these cells are 
mostly glycolytic. According to this theory, then, cancer is a disease of mitochondrial dysfunction. 
However, healthy cells produce energy through oxidative phosphorylation, in which the product 
of glycolysis, pyruvate, is oxidized in the mitochondria, and thus these healthy cells are mostly 
oxyolytic. Very few studies so far have explored the metabolic profiles of CSCs. Several studies 
suggest that CSCs are mostly glycolytic, while others speculate that these cells are oxyolytic 
[45,46]. Recently, Folmes and colleagues documented reprogramming of somatic cells into 
pluripotent cells and demonstrated that a shift from oxidative phosphorylation to glycolysis in 
differentiated somatic cells is required for reprogramming of these cells into pluripotent stem 
cells [47]. Based on this study, it is possible that a non-CSC population is reprogrammed into 
CSCs during the development of cancer. In support of this, hypoxia has been shown to increase 
breast CSCs regulated by hypoxia-inducible factor 1 alpha (HIF1α) [9]. 
To conclude this part of the review, there are two major unknown challenges associated with the 
elucidation of the origin of CSCs. The preceding discussions conclude that de-differentiation is 
one of the driving factors for CSC generation, and in this regard, it seems possible that CSCs 
show plasticity. CSCs typically differentiate and form heterogeneous populations. At the same 
time, a differentiated non-CSC population, in response to certain conditions including toxic 
exposure and mutations, may de-differentiate into CSCs and lead to further tumor progression. 
However, further evidence is necessary to shed light on the complex phenomenon of CSC 
plasticity, given that tumors contain a heterogeneous population with different phenotypes 
and genotypes. Another challenge in the study of CSCs is the identification of differentiated non-
CSC populations that undergo transformation and de-differentiation. 
The stem cells in a tissue are known to divide and self-renew for long periods, and studies have 
suggested that these stem cells are more susceptible to mutations. However, no study has been 
documented in the literature demonstrating the accumulation of mutations in these long-lived 
dividing stem cell populations. The suggestion that a metabolic shift can reprogram somatic cell 
into pluripotent stem cells also requires further investigation and in-depth study as such a shift 
might relate to cancer. 
Since CSCs were first identified, their origin has been a pronounced mystery. Toxic exposure, 
mutations, metabolic shift, cellular plasticity, and de-differentiation have been suggested as 
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contributing factors for the origin of CSC. Finding a link between all these factors and investigating 
whether these events occur sequentially are challenges. 
4. Manifold existence of cancer stem cells and its impact on cancer 
biogenesis and aggressiveness 
So far, a description of the existence of CSCs is controversial, as different studies have shown 
different CSC markers (Table 1). The lack of a universal CSC marker makes it difficult to 
characterize CSCs in various kinds of cancer, and much of the evidence suggests that CSCs are 
heterogeneous. According to this, tumors consist of distinct CSC populations with specific 
phenotypes and clonogenic potentials. In this part of the review, we will describe the CSC 
heterogeneity or specific clonogenic populations of CSCs in various cancers and their impact on 
cancer biogenesis and aggressiveness. 
4.1. Cancer stem cell heterogeneity in liquid tumors: establishment of original CSC 
paradigm 
The concept of CSCs was first recognized and analyzed in most detail in liquid tumors such as 
acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and acute lymphoid 
leukemia (ALL). Bonnet et al., have identified CD34+CD38-leukemic stem cells in AML for the first 
time and demonstrated that this particular subset of leukemic stem cell population shows self-
renewal, proliferative and differentiation potential and induce leukemic transformation in 
NOD/SCID mice [48]. Later, Cox et al., have shown that cells with CD34+CD19-CD10- phenotype 
are long term proliferative cells with tumorigenic potential [49]. Later studies in leukemia showed 
distinct CSC populations including CD34-Lin+CD38+, CD45RA+, CD34+CD38−CD71−HLA-DR−, 
CD34+CD38− CD123+, T cell immunoglobulin mucin 3 (TIM3+) and CXCR4+ [50,51,52,53,54]. 
However, CSCs in solid tumors display a completely distinct set of markers as described below. 
4.2. Cancer stem cell heterogeneity in solid tumors 
CD133+ and ABCG2+ population from surgical biopsy samples of melanoma patients showed an 
increased tumor initiating property in vivo [55]. In NOD/SCID mice, ALDH+ melanoma 
cells showed increased tumorigenicity as compared to ALDH- population suggesting the 
existence of ALDH+ CSCs in melanoma [56]. Circulating melanoma cells 
showed Nestin expression suggesting this protein as a potential marker for melanoma 
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metastatic stem cells [57]. Transplantation of CD271+ melanoma cells into engrafted human skin 
produced melanoma tumors, while CD271- population did not, suggesting the CD271+ population 
as a distinct melanoma stem cell population [58]. Fang et al., showed a small proportion 
of CD20+ population as melanoma stemness population [59]. 
Furthermore, bladder tumor consists of distinct heterogeneous CSC populations. For 
example, CD44+BCMab1+ population was identified as CSC population in bladder cancer, and 
they have also shown that this CSC population has an increased GALNT1 expression and Hh 
signaling leading to increased tumorigenesis [60]. Also, the CD133+ population also showed 
tumorigenic and stemness potential in bladder cancer [61]. In addition to CD44+ and 
CD133+ CSCs, glioma tumors consist of distinct other CSC subtype populations expressing 
MUSASHI1, NESTIN, CD15, L1CAM, and A2B5 [[62], [63], [64], [65]]. 
A recent emerging study demonstrated that the breast CSCs exist as two distinct populations 
such as epithelial-to-mesenchymal (EMT) CSCs and mesenchymal-to-epithelial (MET) CSCs 
[66]. Evidence from this study showed that EMT CSCs (Vimentin+ and EpCAM−) are quiescent; 
however, MET CSCs (Vimentin− and EpCAM+) are proliferative [66]. Another study demonstrated 
that single CD49f+CD24-CD44+ cell-derived clones show aggressive phenotype and activation of 
OCT4/SOX2/lincRNA-RoR signaling suggesting that this subset of the population is also a 
stemness population in breast tumors [67]. 
In contrast, a different set of CSC populations were identified in gastric cancer. Li et al., have 
shown that invasive intestinal-type gastric cancer is originated from Lgr5+ stem cells. Also, 
Lgr5+CD54+ cells showed elevated expression of pluripotent and EMT markers in gastric cancer 
[68]. Apart from these, ALDH+ and CD133+ populations were identified as CSCs in gastric cancer 
[69]. A similar subset of CSC populations was also identified in colorectal tumors. A different 
subset of CXCR4+Lgr5+ expressing population showed significant tumorigenic activity in 
colorectal cancer [70]. Also, CD133+ CSCs showed increased tumorigenicity, and a subset of 
CD133+CXCR4+ CSCs showed increased metastatic potential along with poor survival in 
colorectal tumors [71]. DCLK1 has been showed to be associated with increased tumorigenesis, 
and knockdown of DCLK1 reduced tumor cell pluripotency and pro-survival signaling in colorectal 
cancer, suggesting the existence of a distinct DCLK1+ subset of CSCs in colorectal tumors [72]. 
In addition to CD44+, ALDH+ and CD133+ CSC populations, ovarian and head-and-neck 
tumors consist of distinct CSC subtype populations. CD117+ CSCs in ovarian cancer is 
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associated with poor survival and increased tumorigenesis. [73]. In contrast, head and neck 
tumors harbor CD98+, CD200+ and GRP78+ CSC population [74]. Among these, CD200+ CSCs 
showed increased stemness features and resistance to chemo and radiation treatments [75]. 
Similarly, liver tumors consist of CD133+, ALDH+ and CD44+ cancer stemness populations 
[76,77]. Also, CD90+CD44+ subset of liver cancer cells showed elevated tumorigenicity 
and metastasis in immunodeficient mice [78]. CSCs in lung tumor is also highly heterogeneous, 
and for example, CD44+, ALDH+, and EpCAM+ maintain stemness and tumorigenic potential 
in lung adenocarcinoma [79]. In addition, lung tumor also consists of highly tumorigenic 
CD166+CD44+ CSC population [80]. 
Pancreatic tumor harbors several distinct stemness populations such as CD44+, CD133+, 
ALDH1+, ABCG2+ (SP), EpCAM+, autofluorescence+ (AF) and CXCR4+ CSC populations [81]. 
Hermann et al., have shown that CD133+ population is highly tumorigenic and a CD133+CXCR4+ 
subset of the population is highly metastatic in pancreatic cancer [11]. Recently, an emerging 
study demonstrated that intracellular autofluorescence (AF) was used as a CSC marker in 
pancreatic cancer [82]. Riboflavin-loaded intracellular vesicles expressing ABCG2 shows 
autofluorescence and maintains stemness potential in pancreatic CSCs [82]. ABCG2 receptors 
on cell surface confer chemo-resistance to cells, and cells with a higher number of these 
receptors are considered stem cells or side population (SP). Hence, ABCG2 is also used as a 
CSC marker in various cancers [83,84]. The autofluorescence assay and SP assay are mainly 
based on ABCG2 expression. However, the autofluorescence population did not overlap with SP 
cells, further confirming and supporting the non-uniqueness of stemness markers in CSCs. 
CD44+ and CD133+ cells have been proposed to be CSCs of medullary thyroid carcinoma [85], 
endometrial cancers [86] and rectal cancer [87]. Also, choroidal and ciliary body melanoma CSCs 
express CD117 and CD15 markers [88]. Overall, these studies suggest that tumors of various 
organs consist of distinct CSC populations with different stemness phenotypes. 
4.3. Evidence for the existence of distinct CSC population based on nuclear transcription 
factors 
Studies have demonstrated that specific embryonic genes, including Oct3/4, SOX2, 
Nanog, KLF4, and PAF1/PD2 are recapitulated during cancer initiation and progression. Most 
recently, SOX2 was identified as a CSC prognostic marker in pediatric sarcomas and prostate 
cancer [89,90]. Polycomb group proteins (e.g., EZH2, BMI1) are significant drivers of stem cells, 
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and a group of researchers from the University of Queensland has proposed BMI1 and EZH2 as 
prostate and oral CSC markers, respectively [89,91]. We have identified the novel role of 
PAF1/PD2 in the maintenance of ovarian and pancreatic CSCs, demonstrating that PAF1/PD2 
interacts with Oct3/4 or PHF5A and maintains the stem cell features of ovarian/pancreatic CSCs 
[92, 93, 94]. It is also known that VEGF promotes stemness and has been shown as a breast 
CSC marker [95]. 
4.4. Metabolic profiles of CSCs 
A previous study demonstrated that self-renewing normal pluripotent stem cells (PSCs) are 
glycolytic and that during differentiation, these PSCs switch their metabolic profile from glycolytic 
to oxidative phosphorylation [96]. According to this study, even CSCs should be glycolytic, since 
self-renewal is one of the characteristic properties of normal stem cells and CSCs. Ciavardelli et 
al. have demonstrated that CD44+ CD24-breast CSCs are glycolytic and that the inhibition 
of glycolysis reduced proliferation of this CSC population [45]. Also, radio and drug-resistant 
populations in nasopharyngeal carcinoma relied on glycolysis for their energy needs. However, 
upon differentiation, this CSCs shifted their metabolic profile from glycolytic to oxidative 
phosphorylation [97]. In contrast, reduced glycolysis and increased mitochondrial oxidative 
phosphorylation are characteristic features of CSCs. Song and colleagues demonstrated that 
colon CSCs utilize mitochondrial oxidative phosphorylation for their energy needs [98]. Similarly, 
glioma and leukemic stem cells have been reported to be oxyolytic [99]. 
Based on the above studies, there is wide metabolic variability in CSCs. Recent research 
suggests the existence of distinct CSC populations, and it may be possible that a specific CSC 
population subtype shows a unique metabolic profile. Gammon and colleagues showed that there 
exist two different types of CSC populations in breast tumors, EMT CSC, which is a CD44+CD24- 
and quiescent population, and MET CSCs, which comprise ALDH+ and cycling population [50]. 
The group studied the metabolic profiles of these two CSC subtypes and suggested that EMT 
CSCs are glycolytic, whereas MET CSCs are oxyolytic [100]. 
4.5. Plasticity of cancer stem cells 
Based on the discussion above, CSCs in a tumor is heterogeneous. In addition to this complexity, 
CSC plasticity is another process, in which there is a transformation between non-stem cells to 
stem cells or vice versa contribute to the development of heterogeneity within a tumor. One of the 
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significant processes of CSC plasticity is EMT. As described above, studies in breast cancer 
showed two distinct CSC populations such as EMT CSCs and MET CSCs, which maintain the 
plasticity [66]. In pancreatic cancer, metformin treatment induced the transition of oxidative CSCs 
into drug-resistant glycolytic CSCs, further confirming the plasticity of CSCs [8]. 
In addition to these studies, other reports also demonstrated the transformation of non-CSC into 
CSCs. For example, JARID1B, a histone demethylase has been shown to regulate 
tumorigenicity, and however, cells negative for JARID1B also acquired self-renewal suggesting 
the plasticity of melanoma CSCs [101]. ZEB1, an EMT transcription factor induces the plasticity 
of CSCs by converting non-CSCs into CSCs in breast cancer [102]. The combined induction of 
pluripotent transcription factors POU3F2+SOX2+SALL2+OLIG2 reprograms glioblastoma cells 
into glioma CSCs [103]. Moreover, silencing of PTEN, a tumor suppressor gene induced 
stemness features in mammary epithelial cells resulting in the development of pre-malignant 
lesions [104]. 
To sum up this section, the current major challenge in CSC biology is the lack of a specific CSC 
marker that can be used to characterize virtually any kind of CSC from any cancer. Self-renewal 
and cellular quiescence can be exploited to characterize CSCs; however, these properties are 
common in both normal stem cells and CSCs. To overcome these challenges, the scientific 
community proposed various biomarkers for CSCs, but great disagreement remains within the 
scientific community regarding CSC biomarkers. Different studies have proposed different 
markers, but these markers are not unique to a particular cancer type. Studies have also proposed 
different markers for CSCs from different cancers. These studies conclude that there is no unique 
marker for CSCs in different cancers. On the other hand, this discussion can open doors to a 
novel hypothesis that tumors consist of heterogeneous and distinct CSC populations, and that 
each CSC subtype shows a unique metabolic profile and clonogenic potential that results in the 
derivation of heterogenic populations within tumors. Isolation of CSCs from various cancers using 
various established markers and investigating the common property or marker expression in all 
these CSC population types may further reveal a single, unique property in CSCs. Such 
investigation can also address whether different types of CSCs exist, and, if so, describe the 
function of each type of CSC within tumors. 
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5. Maintenance of “Cancer stemness.” 
Controlled signaling networks in normal stem cells maintain tissue homeostasis; however, loss of 
control in these networks and consequent abnormalities result in elevated self-renewal, increased 
survival and increased proliferation that lead to CSC generation and enhanced CSC 
maintenance. Stem cell niche, various signaling molecules, and transcription factors maintain 
stemness homeostasis in normal stem cells. Similarly, CSC niche, mutations and various 
abnormal extrinsic and intrinsic signals de-regulate the pathways leading to the emergence and 
maintenance of CSCs. In this section of the review, we will discuss the role of tumor 
microenvironment (TME), specific stemness signaling molecules and transcription factors in CSC 
maintenance in detail (Fig. 3). 
5.1. Role of tumor microenvironment in the maintenance of CSCs 
The interactions between CSCs and its “niche” a specific tumor microenvironment (TME) of CSCs 
maintain “stemness.” Stromal cells, mesenchymal stem cells, hypoxic regions, inflammatory 
cells, extracellular matrix (ECM) and angiogenesis are the significant components of this specific 
microenvironment that induce and maintain stem cell features in CSCs. The effect of 
inflammatory stroma on the dedifferentiation and generation of CSCs was shown recently by 
Schwitalla et al. in which they showed that increased activation of NF-kB, a transcription factor in 
the inflammatory TME elevates Wnt signaling and induces dedifferentiation of non-stem cell 
population into CSC population in intestinal tumors [105]. Another evidence for TME mediated 
maintenance of CSCs showed that Notch signaling prevents CSCs from differentiation by 
inhibiting the differentiation signals coming from TME [106]. Besides, mesenchymal stem cells 
support CSC by secreting a variety of cytokines such as CXCL12 and interleukins that induce 
stemness through NF-kB pathway [107]. In TME, CSCs escape from NK cell-mediated cytotoxic 
effects, and for instance, CD133+ CSCs express low levels of MHC-class 1 molecules leading to 
poor recognition by NK cells in glioblastoma [108]. TME hypoxia also promotes tumor 
progression and therapy resistance by preferentially maintaining CSCs in breast cancer [109]. 
Human renal CSCs release macrovesicles (containing miRNAs and mRNAs for VEGF) and 
induce angiogenesis [110]. These studies collectively suggest that TME is functionally essential 




5.2. Wnt molecules in the maintenance of self-renewal of cancer stem cells 
Wnt proteins are involved in a signaling mechanism that maintains the ability of self-renewal in 
stem cells. The Wnt ligands bind to different receptors and result in the activation of either 
canonical or non-canonical signaling pathways that control various cellular functions such as self-
renewal, proliferation, survival, and differentiation. In the canonical Wnt signaling pathway, the 
Wnt ligand binds to the Frizzled receptor (Fzd) and low-density lipoprotein receptor-related 
protein 5/6 co-receptors (LRP5/6), leading to the formation of the Fzd/LRP5/6 complex. As a 
result, Axin and disheveled (Dvl) are recruited to the plasma membrane, leading to the disruption 
of the β-catenin degradation complex. Free and active forms of β-catenin in the cytoplasm then 
translocate to the nucleus. In the nucleus, these molecules form complexes with T-cell factor 
(TCF)/lymphoid enhancer factor (LEF) and lead to the transcriptional activation of Wnt target 
genes [111]. Various non-canonical Wnt molecules such as Wnt4, Wnt5a, Wnt9b, Wnt10a, and 
Wnt10b are involved in the fine-tuning of the canonical Wnt signaling mechanism [112]. These 
non-canonical Wnt molecules bind to the Fzd receptor and Ror1/2 co-receptor, thereby activating 
non-canonical signaling pathways such as the Wnt/Calcium (Ca2+) and Wnt/planar cell 
polarity (PCP) pathways. 
Previous studies have shown that Wnt signaling regulates the maintenance of healthy intestinal 
stem cells. The regenerative capacity of intestinal stem cells is reduced with the decline in 
canonical Wnt signaling, suggesting that Wnt signaling plays a vital role in the improvement of 
aging of these cells [113]. Intestinal stem cell markers such as CD44 and Lgr5 are also the direct 
target genes of the Wnt pathway [114]. It was also shown that Lgr5+ cells are multipotent intestinal 
stem cells, rapidly cycling and long-lived, with high regenerative capacity [114]. Reduced 
expression of DKK1, an antagonist of the Wnt pathway, increased the stemness of intestinal stem 
cells, suggesting the importance of this signaling in intestinal stem cells [115]. Previous studies 
have shown that Wnt signaling maintains the self-renewal of mammary stem cells, and inhibition 
of Wnt signaling reduced the stemness of mammary stem cells [116]. Protein C receptor, a Wnt 
target gene, has been shown to maintain mammary stem cells [117]. Another Wnt target gene, 
Sox9 has been shown to maintain the stemness state of mammary stem cells [118]. Lgr4, 
a leucine-rich repeat G-protein coupled receptor, is involved in stemness maintenance of 
intestinal and epidermal stem cells. Lgr4 activates Sox2 through Wnt signaling to maintain 
stemness in mammary stem cells [119]. In contrast to the stemness maintenance role of Lgr4, a 
recent study has shown that Lgr4 upregulation also induces the differentiation of prostate stem 
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cells [120]. These studies suggest that Wnt signaling has distinct roles in different organs and the 
importance of Wnt signaling in the maintenance of normal mammary stem cells. 
Mutations in Wnt signaling molecules are the primary drivers of intestinal cancers, including 
colorectal cancer. A loss of function mutation in APC, a tumor suppressor, and a Wnt signaling 
controller, leads to the deregulation of the Wnt pathway and the emergence of colorectal CSCs, 
and consequently to the initiation and progression of colorectal cancer [121]. Mutations in the 
GSK3β phosphorylation site in β-catenin leads to aberrant Wnt signaling and development of 
colorectal cancer [122]. Wnt signaling has also been shown to be involved in the maintenance of 
colon CSCs [123]. Inhibition of Wnt signaling reduces the stemness of breast CSCs and 
suppresses breast cancer metastasis [124], while the activation of Wnt/β-catenin signaling 
increased mammosphere formation ability and enriched breast CSCs [125]. 
5.3. Hedgehog (Hh) in cancer stem cell maintenance 
In addition to Wnt, Hh proteins maintain the self-renewal property of stem cells. The Hh signaling 
pathway begins with the binding of three ligands: Indian hedgehog or desert hedgehog or sonic 
hedgehog to Patched1 (PTCH1) or Patched2(PTCH2) receptors. After this binding, the receptor-
mediated inhibitory effect on Smoothened (SMO), a G-protein coupled signaling protein, is 
removed, leading to the activation of a signaling cascade that facilitates the nuclear translocation 
of GLI family transcription factors (a glioma-associated oncogene homolog transcription factors). 
Once GLI transcription factors enter the nucleus, they bind to DNA and regulate various genes 
such as Fox, Myc, and Cyclin D [126]. 
Hh signaling regulates significant cellular and molecular events during embryo development and 
maintains adult tissue homeostasis. It has been shown that Hh signaling regulates the 
differentiation of ESCs. The signaling is highly activated during the differentiation of ESCs and 
effects the lineage determination of ESCs [127]. During embryonic chick lung development, the 
expression patterns of various Hh signaling proteins such as PTCH1 and GLI was also observed 
[128]. These studies collectively suggest the importance of Hh signaling during 
embryonic organogenesis and for the regulation of ESC. 
On the other hand, Hh signaling also regulates the stemness of various CSCs. Studies have 
suggested that multiple myeloma (MM) stem cells, for example, are CD138 negative and that the 
inhibition of Hh signaling in these cells reduces their clonal ability, suggesting its importance in 
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maintaining MM stem cells [129]. Cyclopamine-mediated inhibition of Hh signaling in GBM 
neurospheres reduced other stemness markers, such as Nanog, Sox2, and Nestin [130]. The Shh 
target gene, BMI1, is highly upregulated in CD44+ CD24- breast CSCs and maintains the 
regulation of self-renewal of breast CSCs [131]. Inhibition of SMO using its antagonist, GDC-
0449, and consequent inhibition of Hh signaling, led to apoptosis of pancreatic tumorspheres 
[132]. These studies implicate Hh signaling in the regulation of stemness in CSCs. 
5.4. Notch signaling and self-renewal maintenance 
The Notch signaling pathway also governs the self-renewal of stem cells and the development 
and homeostasis of various tissues. Notch signaling is initiated when two cells, one signal 
releasing and the other signal receiving, are in contact with each other. The signal-releasing cell 
produces a ligand, which binds to the receptor on the signal receiving cells and thereby cleaves 
and translocates the intracellular part of the Notch receptor into the nucleus. Once this enters the 
nucleus, it acts as a transcriptional co-activator. The binding of the Notch transcriptional co-
activators to target gene promoter regions leads to the activation of its target genes, including 
Myc, p21, and Hes1 [133]. 
The stemness property of adult normal stem cells in various adult tissues is maintained by Notch 
signaling. Lgr5+ cells in intestinal tissues are intestinal stem cells, and this Lgr5+ population is 
responsible for the homeostasis of intestinal tissue. Recent studies have shown that the inhibition 
of Notch signaling reduces the Lgr5+ intestinal stem cell population [134]. Notch signaling also 
mainly regulates the maintenance of neural stem cells. Inhibition of Rbpj, a Notch receptor-
effector molecule, in the adult brain led to the differentiation of neural stem cells into neurons, 
suggesting that the signaling is crucial for the maintenance of neural stem cells [135]. 
As in normal stem cells, Notch signaling also plays a crucial role in the regulation of stemness or 
self-renewal in CSCs, and abnormal activation of the pathway leads to increased self-renewal of 
CSCs. For instance, Notch signaling controls pancreatic CSCs in pancreatic ductal 
adenocarcinoma (PDAC), and silencing of Hes1, a Notch pathway target gene, reduced the 
percentage of pancreatic CSCs [38]. Hes1 upregulation also increases the number 
of CD133+ cells, side populations, and the ability to form tumorspheres in colon cancer. The 
stemness of renal cell carcinoma CSC has also been shown to be regulated through the Notch 
pathway. Blockade of Notch receptors using Numb, an endogenous inhibitor of Notch receptors 
in CD133+CD24+ renal cell carcinoma CSC, led to a reduction in self-renewal and drug 
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resistance in these CSCs [136]. Treatment with gamma-secretase inhibitor IX (GSI), a Notch 
inhibitor, inhibited proliferation and induced apoptosis in CD44+gastric CSCs [137]. These studies 
collectively suggest the importance of Notch signaling in the maintenance of stemness in CSCs. 
5.5. ABC transporters in the maintenance of drug resistance in CSCs 
Drug resistance in CSCs is caused by multiple factors including ABC transporter-mediated drug 
efflux, immune escape due to loss of MHC class 1 molecule, extracellular acidic pH, ALDH 
enzyme-mediated cellular detoxification system and increased DNA repair ability. Among these, 
the ABC transporters mediated drug efflux mechanism is highly activated and unique in CSCs. 
Previous studies have shown that aberrant regulation of ATP binding cassette (ABC) transporters 
leads to drug resistance of CSCs [138]. Three major ABC transporters, ABCB1 (MDR1), ABCC1, 
and ABCG2, have been demonstrated for the drug resistance in CSCs. Multiple signaling 
mechanisms have been shown to regulate the expression of ABC transporters. MDR1, a 
multidrug-resistant gene, is responsible for the drug resistance of CSCs, and the MDR1 gene is 
directly regulated by the MYC oncoprotein [139]. Also, the expression of ABCG2 is regulated by 
an increase in JNK1 signaling [140]. HIF2α and PPARγ/PTEN/PI3K/Akt have been shown to 
regulate the ABCG2 gene in breast cancer [141,142]. Increased expression of the estrogen 
receptor β (ERβ) induces cancer by regulating ABCG2 [143]. NRF2, a redox-sensing transcription 
factor, regulates ABCG2 in lung CSCs [144]. The YAP pathway (Hippo pathway) is a highway for 
drug resistance in tumors [145]. On the other hand, Notch1 signaling has been shown to regulate 
the ABCC1 transporter, leading to increased drug resistance in prostate CSCs [146]. In summary, 
ABCB1, ABCC1, and ABCG2 drug efflux transporters are the major players in the drug resistance 
of CSCs. Developing therapeutic strategies to target these transporters may be a better strategy 
to eliminate CSCs from tumor bulk. 
5.6. Anti-apoptotic proteins and its importance in CSCs 
Anti-apoptotic pathways are primarily responsible for drug resistance in CSCs. Identification of 
various targets specifically involved in anti-apoptosis of CSCs is crucial for developing CSC-
targeted therapies. Most studies have repeatedly shown that up-regulation of various anti-
apoptotic proteins, such as Bcl-2, Mcl-1, c-FLIP, and survivin, and the down-regulation of pro-
apoptotic proteins such as Bid, lead to increased drug resistance in CSCs. Bcl-2, an anti-apoptotic 
protein, is required for the survival of leukemia stem cells [147]. Glioma stem cells also showed 
increased expression of Bcl-2, along with another anti-apoptotic protein, Mcl-1 [148,149]. Another 
34 
 
significant anti-apoptotic protein, c-FLIP, exerts its function by activating major signaling 
molecules, such as Akt and ERK. c-FLIP is overexpressed in breast CSCs and leads to their 
increased survival [150]. Survivin, another anti-apoptotic protein, is up-regulated in breast CSCs 
and to lead to therapeutic resistance of breast CSCs [151]. Targeting Bid, a proapoptotic protein, 
in ovarian CSC reduced the stemness of these cells, suggesting that Bid is responsible for the 
elevated stemness in ovarian CSCs [152]. Targeting these pro-apoptotic and anti-apoptotic 
proteins in CSCs may increase the sensitivity of CSCs to drug-mediated cell death. 
5.7. NF-ƘB in CSC maintenance 
One of the many characteristic features of CSCs is epithelial to mesenchymal transition [50]. 
Recent studies have suggested that EMT is not only responsible for metastasis, but also for drug 
resistance the TWIST-mediated NF-ƘB pathway regulates EMT in papillary thyroid 
carcinoma [153]. Besides, SDF-1 activates NF-ƘB, leading to the induction of EMT in breast 
CSCs [154]. The multidrug-resistant gene, MDR1, is regulated by CD133 and the DNA dependent 
protein kinase (DNA-PK) via the PI3K- or Akt-NF-κB network [155]. Osteopontin, an oncoprotein, 
induces hepatocellular CSCs through an integrin- NF-κB-HIF-1α pathway [156]. Activation 
of TLR3 was also shown to induce the co-activation of β-catenin and NF-ƘB, leading to the 
promotion of breast CSCs [156]. In addition to various signaling molecules, miRNAs also induce 
CSCs by activating the NF-κB pathway; for instance, Let7a induces mammosphere formation by 
activating the Ras/NF-κB pathway [157]. 
Given these results, targeting ABC transporters, pro, and anti-apoptotic molecules and NF-κB 
together may be proved to be an effective therapeutic strategy to eradicate CSC populations from 
tumor bulk. 
5.8. HIF1-mediated metabolic alteration in CSCs 
Hypoxia-inducible factor 1 (HIF1) is a transcription factor that mediates metabolic configuration 
under hypoxic conditions. HIF1 consists of two subunits, HIF1α (controlled by oxygen) and HIF1β 
(expressed constitutively) [158]. HIF1α, under normoxic conditions, is also degraded by oxygen-
dependent prolyl-hydroxylases (PHD1–3). Hypoxic conditions or inhibition of PHD enzymes 
increases the stabilization and nuclear translocation of HIF1α, where it activates its target 
metabolic genes such as glucose transporters (GLUT1) and pyruvate dehydrogenase kinases 
(PDK1-3) and results in the switch from mitochondrial oxidative phosphorylation to glycolysis. 
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Increased expression of GLUT1 elevates glucose uptake by cells, and the augmentation of 
PDK1-3 expression inhibits oxidative phosphorylation by inhibiting pyruvate 
dehydrogenase (PDH). Furthermore, HIF1α activates pyruvate kinase (PKM2) gene 
transcription, and this is facilitated by its interaction with the PKM2 gene. PKM2 catalyzes the final 
step of glycolysis by dephosphorylating phosphoenolpyruvate to pyruvate. Thus, HIF1α plays an 
important role in increasing glycolysis and decreasing oxidative phosphorylation [158]. 
A recent study demonstrated that reprogramming of a somatic cell into a pluripotent stem 
cell requires a metabolic shift from oxidative phosphorylation into glycolysis [158]. In detail, 
the transfection of dermal fibroblasts with pluripotent factors such as OCT4, SOX2, KLF4, and c-
MYC increases expression of HIF1α, which in turn activates its target genes, including PDK1, 
PDK3, and PKM2. The activation of PDK1 and PDK3 inhibits PDH, leading to a shift from oxidative 
phosphorylation to glycolysis. These results suggest that a metabolic shift from mitochondrial 
respiration to glycolysis is mandatory during the reprogramming of somatic cells into stem cells. 
In terms of CSCs, HIF1α expression is elevated in prostate CSCs, suggesting that an HIF1α 
signaling-mediated glycolytic shift may be required for maintenance of CSCs [159]. Also, HIF1α 
has been shown to increase β-catenin transcription and to result in the activation of Wnt signaling 
in leukemia stem cells [160]. Iida et al. showed that HIF1α activates Oct3/4 and Sox2 expression 
and induces CD133 expression under hypoxic conditions [161]. Despite this evidence, it is not 
known whether the activation of HIF1α can completely reprogram a cancer cell or a differentiated 
cell into a CSC through a HIF1α-mediated glycolytic shift. 
5.9. Myc and Nanog maintain metabolic alteration in CSCs 
The oncoproteins of the Myc family (MYC, MYCN, and MYCL) control cell proliferation in various 
cancers. Apart from this, these oncoproteins have been shown to play a crucial role in metabolic 
reprogramming under cancerous conditions. MYC activates various metabolic genes, including 
GLUT1, ENO1, HK1, LDHA, and PKM2, and thus regulate the uptake of glucose, glycolysis, 
and lactic acid production. MYC has a further significant role in the regulation of metabolic 
pathways in stem cells. The MYC oncoproteins (MYC and MYCN) present in neuronal progenitor 
cells activate HK2 and LDHA, leading to their increased reliance on glycolysis for energy 
production. However, during differentiation of these neuronal progenitor cells into neurons, a shift 
from glycolysis to oxidative phosphorylation was observed that led to a reduction in MYC and 
MYCN proteins as well as in the glycolytic enzymes [162]. 
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Pancreatic CSCs are oxyolytic as the inhibition of MYC contributes to the suppression of 
mitochondrial respiration in these CSCs [8,163]. Moreover, treatment with metformin, an inhibitor 
of mitochondrial respiration, induced apoptosis in pancreatic CSCs. However, a tiny subset of 
pancreatic CSCs developed resistance to metformin and displayed intermediate metabolic 
phenotype. Metformin-induced Myc overexpression also led to a shift from oxidative 
phosphorylation into glycolysis in these metformin-resistant CSCs. 
Nanog is a transcription factor required for the maintenance of pluripotency in stem cells. It binds 
to the promoter of the genes involved in oxidative phosphorylation, and its overexpression 
reduces the expression of mitochondrial respiration genes but increases mitochondrial fatty acid 
oxidation in liver CSCs. The upregulation of genes involved in mitochondrial respiration 
interestingly reduces self-renewal of liver CSCs [164]. Nanog thus maintains cancer stemness of 
liver cancer cells by inhibiting mitochondrial oxidative phosphorylation and by inducing fatty acid 
oxidation. 
6. Cancer stemness in metastasis 
6.1. “Seed” and “Soil” theory of metastasis 
Although there are novel targeted therapies and advanced surgical techniques available to reduce 
or remove primary tumors, cancer remains one of the leading causes of mortality worldwide with 
the primary cause of cancer-related deaths being the progressive development of metastasis. 
Organ-specific metastasis has been a mystery to researchers for over a century. In 1889, Stephen 
Paget proposed the “seed” and “soil” theory, in which tumor cells (seed) from the primary site 
travel to a distant organ (soil), which in turn is a favorable environment to support the colonization 
and growth of the tumor cell. A specific organ, according to this theory, can provide a suitable 
environment for the growth of a specific tumor cell, resulting in the organ-specific metastasis of 
given tumor cells [165] (Fig. 4). In support of this notion, it has also been shown that tumor cells 
create an environment in targeted distant organs that are suitable for the growth of future 
metastatic cells [166]. 
6.2. Impact of cancer stem cell heterogeneity on the establishment of organotropic 
metastasis 
Previous studies have shown that CSCs can not only initiate and aggravate cancer but that they 
are also involved in metastasis. However, the role of CSCs in this organ-specific metastasis and 
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the formation of a pre-metastatic niche is poorly understood in the literature. Most studies suggest 
that metastatic cells show a CSC phenotype. In pancreatic cancer, the CD133+ cell population is 
highly metastatic. CXCR4 expressing CSCs showed an increased tumorigenic property and 
elevated metastatic potential. In colon cancer, CD26+CSCs are known to have metastatic 
potential. ALDH+ and CD44+CD24- breast CSCs also show high metastatic potential [167]. 
However, it is not completely understood in the literature whether heterogeneous CSC subtype 
populations with a specific phenotype and clonogenic potential can metastasize to a specific 
organ. Gao et al. have shown that CD110-positive CSCs show liver organotropism, whereas 
CDCP1 promotes lung tropism in colorectal cancer. CD110+ and CDCP1+ metastatic CSCs in 
colorectal cancer determine organ-specific metastasis [168]. Besides, CXCR4 positive breast 
CSCs have been shown to metastasize to the lymph node and lung. Among CD44+CD24- breast 
CSC populations, a subset of CD44v (variant forms of CD44) populations showed enhanced lung 
metastasis potential [169]. Studies also suggested that distinct CSC populations display 
differential metabolic profiles. For instance, breast tumors consist of EMT CSCs and MET CSCs, 
with EMT CSCs being glycolytic but MET CSCs oxyolytic [100]. In pancreatic cancer, Reichert et 
al. have shown that EMT-MET plasticity is involved in regulating organotropic metastasis. The 
authors in this study believe that epithelial plasticity, which is regulated by P120CTN is an 
important factor for the establishment of cancer cell colonization in liver or lung [100,170]. 
Investigating whether a specific CSC subtype with a specific metabolic phenotype can 
metastasize to a specific organ remains a challenge (Fig. 4). 
6.3. Exosomes in cancer stem cell-mediated metastasis 
Of interest, recent studies also showed that exosomes released by certain primary tumor cells 
travel to a specific target organ and mediate the formation of PMN. The exosomes released by 
primary tumor cells carry integrins α6β4 and αvβ5 to the lung and liver, respectively. The resident 
cells of liver and lung then receive these integrin-containing exosomes, resulting in the activation 
of Src phosphorylation and pro-inflammatory S100 gene expression in these target organs, and 
leading to the formation of PMN [171]. It is unclear whether exosomes released by a specific CSC 
with a specific phenotype can reach and form a pre-metastatic niche in a specific distant organ. 
Cancer cells and CSCs communicate continuously with each other by sharing their protein 
and nucleic acid contents through exosomes [172]. It has been shown that the exosomes derived 
from a stem cell can fuse with a non-stem cell and convert this non-stem cell into a stem cell. In 
this process, the stem cell-derived exosome carries stem cell signature proteins, nucleic acids, 
and other regulatory RNAs, and that they share these contents with the non-stem cell, 
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transforming from a non-stem cell into a stem cell [173]. Based on this finding, it is possible to 
suggest that the exosomes derived from CSCs with a specific phenotype can reach a specific 
organ and can form a pre-metastatic niche in the target organ (Fig. 4). 
7. Concluding remarks 
The CSCs are self-renewing, drug-resistant cells within the tumor bulk. Understanding their origin, 
existence, and maintenance and their role in metastasis is crucial to develop an efficient CSC-
targeted therapy. Apart from cell fusion and horizontal gene transfer, mutations have been shown 
to contribute to the origin of CSCs. External factors, such as hypoxia and toxic exposure, induce 
mutations in differentiated cells and lead to the de-differentiation and reprogramming of these 
cells into CSCs. It is also possible that a metabolic shift can reprogram somatic or 
differentiated cancer cells into CSCs. Most studies suggest the existence of distinct CSC 
population in tumors. The Wnt, Hh, and Notch signaling molecules, along with metabolic 
regulators such as HIF1α, maintain CSC populations within heterogeneous tumors. Recent 
evidence fuels the concept that a specific CSC subtype with subtype-specific clonogenic potential 














Figure. 1. The overall journey of CSCs from origin to metastasis. a) Origin of CSCs. 
Mutations in adult stem cells (ASCs) or differentiated somatic cells can lead to CSC 
origin. Dedifferentiation of somatic differentiated cell in response to various external toxic 
exposures can give rise to CSC phenotype. Other factors, such as metabolic reprogramming, cell 
fusion, and horizontal gene transfer can also induce CSCs. b) Multiple CSC populations reside 
within tumors. CSCs with detoxification systems such as ABCG2-mediated drug efflux 
mechanism and ALDH-mediated aldehyde toxic substance detoxification systems exist in various 
tumors. CSCs expressing cell surface markers such as CD44, CD24, and EpCAM together are 
also significant constituents within various heterogeneous tumors, such as pancreatic tumors. 
Other CSC, which express CD133 and CXCR4, also reside within the same tumor. Intestinal 
tumors consist of Lgr5-expressing CSCs. c) ‘Stemness’ maintenance mechanisms. The 
stemness in CSCs is largely maintained by specific stemness molecules such as Wnt/β-catenin, 
Notch and hedgehog, along with other factors such as YAP, HIF1α, NF-kB, PPARγ, 
and antiapoptotic. d) Role of CSCs in metastasis. The “seed” and “soil” theory, as proposed by 
Stephen Paget, states that primary site tumor cells (seed) travel to a distant organ (soil), and 
colonize and initiate the growth of the tumor. Based on this theory, it is possible that CSCs from 
the primary site will travel to distant organs to initiate metastatic tumors. Another possible view 
suggests that exosomes released by CSCs in the primary site travel to target sites and form the 
pre-metastatic niche (PMN) that supports upcoming CSCs or cancer cells. Another view also 
suggests that distinct CSC population subtypes with subtype-specific metabolic profiles travel to 




























Figure. 2. Different modes of CSC origin. a) ‘Cell fusion’ is a process whereby two cells (one 
stem cell and another cancer cell) fuse together to form CSCs. b) In horizontal gene transfer, 
mutant and fragmented DNA (from a mutant somatic cell that is undergoing apoptosis) is taken 
up by another somatic or cancer cell, leading to the emergence of CSCs. c) Continuous 
symmetric divisions in adult stem cells (ASC) lead to mutation in these cells and give rise to 
CSCs. d) A metabolic shift in somatic or differentiated cells could reprogram these cells into CSCs. 
































Figure. 3. ‘Stemness’ maintenance pathways in CSCs. a) Canonical Wnt/β-catenin pathway 
starts with the binding of Wnt ligand to Frizzled receptor (Fzd) and low-density lipoprotein 
receptor-related protein 5/6 co-receptors (LRP5/6). This results in the recruitment 
of Axin and disheveled (Dvl) to the plasma membrane and leads to protection of β-catenin from 
degradation. Free β-catenin in the cytoplasm then translocates to the nucleus and complexes 
with TCF/LEF to regulate Wnt target stem cell genes. b) Hh signaling pathway is initiated by 
binding of hedgehog class of ligands to Patched1 (PTCH1) or Patched2 (PTCH2) receptors. The 
receptor-ligand binding removes Patched receptor-mediated inhibition of a G-
protein coupled protein, Smoothened (Smo), leading to the nuclear translocation of Gli family 
transcription factors (a glioma-associated oncogene homolog transcription factors). c) Notch 
signaling is initiated when a notch ligand of a cell binds to the notch receptor of an adjacent cell. 
This results in the release of the intracellular part of the notch, which translocates into the nucleus 
and acts as a transcriptional co-activator. When the Notch transcriptional co-activators bind to 
target gene promoter regions, this leads to the activation of its target CSC genes. 
d) Phosphorylation of the cytoplasmic portion of CD133 leads to the phosphorylation of AKT. 
Activated AKT activates the NF-kB pathway, resulting in activation of stemness genes. e) ATP-
dependent mechanism of drug efflux by ABC transporters. f) HIF1α and cMyc 
increase glycolysis (or Warburg effect) and inhibit oxidative phosphorylation in CSCs for 
rapid energy production. HIF1α activates pyruvate dehydrogenase kinases (PDK1-3), which 
inhibit pyruvate dehydrogenase (PDH), and thus inhibits oxidative phosphorylation. c-Myc and 
HIF1α also activate lactate dehydrogenase A (LDHA) to favor the Warburg effect (aerobic 
glycolysis). C-Myc also activates the GLUT-1 receptor, hexokinase, 























Figure. 4. Hypothetical model is showing organ-specific metastasis of CSCs. Distinct CSC 
populations with differential metabolic profiles (either glycolytic, oxyolytic or intermediate) reside 
in heterogeneous tumors. The exosomes released by a specific CSC subtype population in 
the primary tumor site may travel to a specific distant organ to form a pre-metastatic niche (PMN), 




































Tumor Type Type of Cancer stem cell existed 
1 Melanoma CD133+, ABCG2+, CD271+, ABCB5+, ALDH1+, CD20+, 
PD1+ and CXCR6+ 
2 Bladder cancer CD44+, CD67LR+, EMA+, ALDH1A1+ and BCMab1+. 
3 Breast cancer CD44+CD24-, ALDH+, CD44+ALDH+ and 
CD49f+CD24+ 
5 Leukemia CD34+CD38-; CD34-Lin+CD38+; CD45RA+; 
CD34+CD38-CD71-HLA-DR-;CD123+; TIM3+; CXCR4+ 
6 Gastric cancer Lgr5+, CD26+, CD44+, ALDH1+, CD133+ 
7 Colorectal cancer CD133+, CD133+CXCR4+, CD44+, CD166+, ALDH+, 
CD29+, Lgr5+ and CD44+CD24+EpCAM+ 
8 Ovarian cancer CD44+, CD24+, CD117+ and CD133+ 
9 Head and Neck cancers CD44+, CD133+, ALDH+, CD98+, CD200+, GRP78+, 
ALDH+CD44+ and Bmi1+  
10 Liver cancer CD133+, ALDH+, CD44+, CD90+, CD13+, OV6+, 
EpCAM+, ABCG2+ (side population), DLK1+, K19+ 
and c-Kit+  
11 Lung cancer CD44+, CD87+, CD90+, CD117+, CD133+, CD166+, 
ALDH+, BMI1+, EpCAM+ and Side population. 
12 Pancreatic cancer CD44+, CD133+, ALDH1+, Side population, 
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1. Background and rationale 
Pancreatic ductal adenocarcinoma (PDAC) remains the most aggressive and deadliest primary 
cancer with a five-year survival rate of 9 percent (Cancer Facts & Figures 2018, American Cancer 
Society). Recent evidence suggests the presence of cancer stem cell (CSC) populations within a 
heterogeneous pancreatic tumor and provides clues for their association with the aggressiveness 
of PDAC [1, 2]. However, how this CSCs are induced and involved in the metastasis process are 
poorly understood.  
Of several risk factors, cigarette smoking is one of the most important and established risk factors 
for pancreatic cancer. Hoarding experimental and epidemiological evidence has established a 
direct correlation between cigarette smoking and the risk of pancreatic cancer (PC) [3]. Recent 
studies provide ample evidence to the cigarette smoke-mediated induction of pancreatic CSCs. 
An et al. have revealed the critical role of condensed smoke lysate in increasing the size of the 
side population (SP or CSCs) in lung and head & neck cancers [4]. Another study has shown that 
chronic smoke injury in non-small-cell lung cancer is associated with increased K14-positive 
tumor-initiating cells that lead to poor prognosis [5]. 
Further, in breast cancer, it has been shown that nicotine increases CSCs via alpha CHRNA7 
and the PKC-Notch dependent pathways [6].  Cigarette smoke treatment of breast cancer cells 
also resulted in their epithelial-to-mesenchymal (EMT) transition and augmented metastatic 
ability. This was associated with the increased emergence of stem cell-like cells [7]. Apart from 
these malignancies, Hermann et al. have shown that nicotine can promote the initiation and 
progression of Kras-induced PC via Gata6-dependent de-differentiation of acinar cells in mice [8]. 
In our editorial commentary for this proposal, we have provided our view of the role of nicotine in 
pancreatic stem cell activation and acinar de-differentiation [9]. Taken together, all these studies 
support the concept of smoke-induced CSC activation. Despite these pieces of evidence, it is still 
unclear whether and how CSCs are induced in response to cigarette smoking. The first part of 
this thesis is primarily focused on deciphering the mechanistic role of the cigarette smoke on the 
induction of pancreatic CSC populations.  
Further, studies have also reported that CSCs are the major culprits in the metastatic activity of 
pancreatic cancer [1]. Majority of recent pieces of evidence suggest the existence of distinct sub-
types of pancreatic CSCs with sub-type specific stemness features. Previous studies have shown 
the existence of distinct CSC populations in a heterogeneous tumor. For instance, breast tumors 
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consist of two distinct CSC populations such as ALDH+ and CD44+CD24-. The study also 
demonstrated that ALDH+ cells rely on oxidative phosphorylation for their energy needs, whereas 
CD44+CD24- population rely on glycolysis [10]. Recent studies also proposed the propensity of 
a specific cancer cell with specific metabolic profile metastasizes to a specific organ [11]. For 
instance, the liver has a high glycolytic environment, and a metastatic cell required to be highly 
glycolytic to overcome the glycolytic barrier in the liver. Similarly, the lung has an oxidative 
environment, and an upcoming metastatic cell has to be oxyolytic to survive in the lung 
environment [11]. My second goal of this dissertation primarily explores the metastatic function of 
CSCs in pancreatic cancer.  
2. Hypothesis 
Based on the previous studies, we hypothesized that CSCs are induced by cigarette smoking and 
that these CSCs are involved in the organ-specific metastasis process in pancreatic cancer.    
3. Objectives 
Aim 1: To investigate the mechanistic role of cigarette smoke on the induction of CSCs in 
pancreatic cancer. 
Aim 2: To investigate the metabolic and stem cell features of distinct sub-types of pancreatic CSC 
populations. 
Aim 3: To delineate whether these distinct sub-types of CSC populations with sub-type specific 
metabolic and stem cell features metastasize to specific organs.        
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Materials and Methods 
Some of the material covered in this chapter was taken from one published research article: 
Nimmakayala RK, Seshacharyulu P, Lakshmanan I, Rachagani S, Chugh S, Karmakar S, Rauth 
S, Vengoji R, Atri P, Talmon GA, Lele SM, Smith LM, Thapa I, Bastola D, Ouellette MM, Batra 
SK, Ponnusamy MP, Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells 








1. Cell lines and cell culture 
An immortalized human pancreatic nestin-positive epithelial (hTERT-HPNE) cell line was 
obtained as a generous gift from Dr. Ouellette at the University of Nebraska Medical Center. It 
was cultured in Dulbecco’s modified Eagle’s medium (low glucose) with 25% M3 Base Media 
(Incell, San Antonio, TX), supplemented with 5% (vol/vol) fetal bovine serum, 10 ng/mL epidermal 
growth factor, and antibiotics (100 units/mL penicillin and 100 μg/mL streptomycin). The Capan1 
and Miapaca-2 cell lines were cultured in Dulbecco’s modified Eagle’s medium (4.5 mg/mL 
glucose), supplemented with 10% fetal bovine serum and antibiotics (100 units/mL penicillin and 
100 μg/mL streptomycin). Cells were incubated in a humidified incubator at 37°C supplied with 
5% CO2.  
Cells were cultured in stem cell medium: DMEM/F12 (Invitrogen, Grand Island, NY) medium 
supplemented with 1% B27 supplement, epidermal growth factor (20 ng/mL), basic fibroblast 
growth factor (10 ng/mL). In some experiments, cells (2000/well) were plated in 96-well low-
attachment culture plates in 200 μL of the medium. The number of spheres (Φ >100 μm) for each 
well was evaluated after 10 days of culture. Images were captured using Carl Zeiss Confocal 
Fluorescent Microscope (Oberkochen, Germany) using a 488-nm laser. 
For the secondary and tertiary sphere-forming assays, primary spheres or secondary spheres 
were centrifuged and dissociated using enzymatic (trypsin EDTA) and mechanical methods 
(pipette). Then, 2000 cells were seeded in stem cell medium in ultra-low-attachment 96-well 
plates. The total number of spheres (Φ >100 μm) for each well was counted after 10 days of 
culture. 
Miapaca-2 cells were grown under sphere culture conditions in DMEM/F12 medium 
supplemented with 1 % B27 supplement, epidermal growth factor (20 ng/mL), basic fibroblast 
growth factor (bFGF) (10 ng/mL) in the presence and absence of Gemcitabine (3µM) to derive 
drug sensitive and drug resistant CSC populations, respectively. The Miapaca-2 cells cultured 
under adherent culture conditions using 10% DMEM were utilized as differentiated control cells. 
L3.6pL, a spontaneous liver metastatic pancreatic cancer cell line was obtained as a 
generous gift from Dr. Ouellette at the University of Nebraska Medical Center. S2-VP10, a 
spontaneous lung metastatic pancreatic cancer cell line was obtained as a kind gift from Dr. 
Ashok K. Saluja at Miller School of Medicine, University of Miami.  
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2. Animal studies 
Animal experiments were carried out in compliance with the regulations of the University of 
Nebraska Medical Center Institutional Animal Care and Use Committee. Ten-week-old LSL-
KrasG12D(Control) and KrasG12D;Pdx-1 Cre animals were used for cigarette (University of Kentucky 
Reference Cigarette, 3R4F) smoke exposure, and the process of smoke exposure was performed 
for 20 weeks, 3 hours twice a day, using the Teague TE-10C system (Davis, CA) by delivering 
smoke at a rate of 150 mg total suspended particles/m3 [22] (Figure 3A). CS exposure was started 
when KrasG12D; Pdx-1Cre animals begin to form low-grade pancreatic intraepithelial 
neoplasia lesions. Sham animals, exposed to filtered air for the same number of hours and days, 
were used as controls. 
3. Preparation of cigarette smoke extract 
Two 3R4F research cigarettes (University of Kentucky) were used to generate cigarette 
smoke extract (CSE). The detailed procedure for the preparation of CSE was adapted from 
previous studies [1, 2]. Briefly, 2 cigarettes were bubbled through 20 mL serum-free Dulbecco’s 
modified Eagle’s medium (DMEM) (by drawing the smoke into the medium using a vacuum) and 
this solution was considered 100% CSE. CSE after preparation was filtered through a 0.2-μm 
filter (Millipore, Bedford, MA), and stored at −80°C immediately after preparation to prevent 
degradation of cigarette components. Commercially available CSE (C-CSE) (Murthy 
Pharmaceuticals, Lexington KY) was used in some experiments to compare the effect CSE 
prepared in our laboratory with standard C-CSE. According to the manufacturer protocol, C-CSE 
was prepared by burning 3R4F standard research cigarettes (University of Kentucky) using the 
Federal Trade Commission (FTC) smoke machine. The total particulate matter (TPM) retained on 
filters was extracted with dimethyl sulfoxide (DMSO) by soaking and sonication. The extracted 
TPM was packaged as 40 mg/mL solution, which is equal to 3.6 cigarettes/mL. 
4. Liquid chromatography-tandem mass spectrometry analysis of nicotine in CSE 
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) analysis of nicotine in 100% 
CSE was performed using the multiple reaction monitoring (MRM) method as shown previously 
[3]. For calibration standards, nicotine stock (1 mg/mL) solution was diluted to 50, 100, 200, 400, 
and 800 ng/mL in 100% MS grade methanol. For CSE sample preparation, 2 3R4F research 
cigarettes (University of Kentucky) were bubbled through 20 mL of LC-MS grade water (Fisher 
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Chemical, Waltham, MA), and the resulting solution was filtered and considered 100%; 100 μL of 
100% CSE was subjected to speed vacuum evaporation, and the dried sample was dissolved in 
100 μL of 100% LC-MS grade methanol for LC-MS/MS analysis. A 50 ng/mL amount of nicotine 
D4 (Sigma, St. Louis, MO) was added in all samples as an internal standard (IS) control. 
Nexera UHPLC (Shimadzu, Kyoto, Japan) with Acquity UPLC BEH Shield RP18 1.7 μm, 2.1 × 
150-mm column (part #186003376; Waters, Milford, MA) was used for chromatographic 
separation. Mobile phase A is 5 mM ammonium bicarbonate buffer (pH not adjusted), and Mobile 
phase B is composed of acetonitrile: methanol (3:1, vol/vol). The temperature of the autosampler 
was 40°C and the sample injection volume was 5 μL. Flow rate was set to 0.4 mL/min. The 
chromatographic gradient program is described in Supplementary Table 1. Total run time of the 
program is 3 minutes and retention times for nicotine and nicotine D4 (IS) are 2.27 minutes and 
2.29 minutes, respectively. 
LC-MS/MS was performed using the MRM method, using AB Sciex QTRAP 6500 
mass spectrometer (AB SCIEX, Framingham, MA) operated in positive mode. Published MRM 
values of nicotine (m/z 163.2/132.1 and 163.2/117.1) and nicotine D4 (m/z 167.3/121.4 and 
167.3/136), including other published parameters,3, 4 were used for analysis. Electrospray 
ionization parameters are as follows: electrospray voltage of 5500 V, a temperature of 550°C, 
curtain gas of 35 psi, gas 1 of 50 psi, and gas 2 of 50 psi. Analyst1.6 software (AB Sciex) was 
used to acquire data and peaks were integrated using Multiquant (AB Sciex). Peak areas were 
normalized with IS peak areas. A calibration curve was generated and nicotine concentration in 
100% CSE was calculated using GraphPad Prism software (GraphPad, La Jolla, CA). The overall 
nicotine concentration in 100% CSE was 33.073 ± 0.698 μg/mL (P < .001). 
5. Analysis of cellular energy metabolism 
Liquid Chromatography-Tandem Mass Spectrometry Analysis of metabolites in energy 
metabolism: Mass spectrometric metabolomics analyses were performed in collaboration with Dr. 
Daryl J. Murry at the Clinical Pharmacology Laboratory, Department of Pharmacy Practice, 
College of Pharmacy, University of Nebraska Medical Center.   Cells were seeded in 10 cm 
culture dishes and two hours before the collection of metabolites the culture medium was replaced 
with fresh medium. After trypsinization, single cells were counted. Five million cells were used to 
extract metabolites.  Metabolites were extracted (An aliquot of the cell solution was counted using 
Trypan blue staining and a Bio-Rad TC20 automated cell counter. Cells were spun down, washed 
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with PBS, and then the cell pellet was stored at −20 ºC. To each cell pellet, 0.3mL of 2-propanol: 
100 mM NH4HCO3, pH7.4 (1:1v/v), was added, cells were then sonicated, and 300 µL of the 
resulting cell homogenate was used for further preparation. A 10 µL spiking of the IS was added 
to the samples, which were then vortexed. Subsequently, 1.0 mL of methanol was added for 
deproteinization, and then mixture was cooled (-80 ºC) for 10 min. The samples were then 
centrifuged for 10 min at 14,000×g at 4 ºC. After centrifugation, supernatants were transferred to 
glass tubes and dried under a stream of nitrogen at 40◦C. The residues were then dissolvedin100 
µL acetonitrile: water 1:1, v/v) and 3 µL of this solution was injected into the LC–MS/ MS 
system. Metabolites analysis was conducted using a Shimadzu Nexera ultra high-performance 
liquid chromatography (UPLC) system (Columbia, MD, USA) equipped with two pumps (LC-30 
AD), a column oven (CTO-30AS) and an auto-sampler (SIL-30AC). Peak resolution and 
separation for all samples were achieved by using a Mastro C18 (2.0 mm I.D. × 150 mm L., 3 μm) 
equipped with a C18 guard column. The mobile phase consisted of a 15 mM Acetate, 10 mM 
Tributylamine-Water (mobile phase A) and methanol (mobile phase B) at a total flow rate of 0.25 
mL/min. The chromatographic separation was achieved using a25 min gradient elution. Mass 
spectrometric detection was performed on an LC-MS/MS 8060 system (Shimadzu Scientific, Inc., 
Columbia, MD, USA), equipped with a dual ionization source (DUIS) operated in the negative 
electrospray ionization and multiple reaction monitoring mode in order to achieve unit resolution. 
Parameters for multiple reaction monitoring (MRM) detection in the negative mode were as 
follows: Nebulizer gas: 2.0L/min; heating gas: 10L/min; drying gas: 10L/min; interface 
temperature: 350ºC; desolvation line temperature: 250ºC; heat block temperature: 400ºC. Mass 
transitions were monitored at 10 ms dwell times and unit mass resolutions and individual 
parameters. Lab Solutions LCMS Ver.5.80 (Shimadzu Scientific, Inc. Columbia, MD, USA) was 
used for data collection and quantitation. 
Glucose uptake, lactate release and glutamine uptake assays: 10,000 cells were seeded per well 
in 96 well white clear flat bottom tissue culture plate (Corning, ME, USA). Glucose uptake, lactate 
release, and glutamine uptake assays were performed using Glucose uptake-GloTM assay, 
Lactate-GloTM assay and Glutamine/Glutamate-GloTM assay kits (all kits from Promega, 
Madison, USA) by following the manufacturer’s protocol. Luminescence readings were taken 
using Synergy Neo2 multimode reader (BioTek, VT, USA). 
XF96 extracellular flux analysis: Analysis of extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR) were performed using an XF96 extracellular flux analyzer (Seahorse 
Biosciences, North Billerica, MA) as shown previously (Wu et al., 2014). Thirty thousand single 
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cells were seeded per well in 96-well cell culture plates (Seahorse Biosciences, North Billerica, 
MA). Manufacturer’s protocols were used to measure ECAR and OCR.  
6. Cell treatments 
CSE treatment was performed as shown previously [2]. Cells were left untreated or were treated 
with CSE (10 μL/mL or 1%) for 48 hours per passage. We continued this process for 40 passages 
(17 weeks or 120 days) so that cells were exposed to CSE for 80 days (Figure 1A). Similarly, cells 
were exposed to cigarette smoke components, nicotine (Sigma; 2 μM) or 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK) (Sigma; 2 μM) or N-Nitrosonornicotine (NNN) (Sigma; 2 μM) for 
80 days. In some experiments, PD98059 (Sigma; 25 μM; 24 hours), an inhibitor of ERK1/2, and 
Macamylamine (Sigma; 200 μM; 24 hours), specific inhibitor and antagonist of CHRNA7 were 
added in 40th passage cultures, followed by 48-hour stimulation with CSE. In experiments using 
C-CSE, cells were treated with 20 μg/mL C-CSE or an equal volume of DMSO vehicle for 80 days 
by following the same treatment process used for CSE treatment (Figure 1A). 
7. Flow cytometry 
Autofluorescence Assay: Cells with stem cell or cancer stem cell features were analyzed and 
isolated using flow cytometry-based autofluorescence (AF) assay as shown previously [5]. In 
some experiments, riboflavin (30 μM) was added to cells and incubated for 1 hour at 37°C 
followed by AF analysis using BD LSR II Green flow cytometer (BD Biosciences, San Jose, 
CA). DAPI (4′,6-diamidino-2-phenylindole; 1 μg/mL) was used for live cell staining. AF cells were 
excited using a 488-nm blue laser and filters, 530/30 and 585/42 1 550LP Blue Det A-A. AF+ and 
AF− cells were sorted using BD FACS Aria (BD Biosciences) using 488 blue laser and similar 
filters (Blue E-A and Blue F-A). Gating strategy for AF+ and AF− population is shown 
in Supplementary Figure 2A. Data were analyzed using FACS DIVA software (BD Biosciences). 
Aldefluor Assay: The activity of aldehyde dehydrogenase was detected using an ALDEFLUOR 
assay kit (StemCell Technologies, Vancouver, BC, Canada) according to manufacturer 
instructions. Stained cells were analyzed using LSR II Green (BD Biosciences) with the green 




Side population assay: Side population analysis was performed with flow cytometry using Hoechst 
33342 (AnaSpec Inc., Fremont, CA, USA) (5µg/ml) Verapamil (Sigma) control, an inhibitor of ABC 
transporters, was used for SP identification at 50 µM final concentration. 
Analysis of stem cell surface markers: One million cells in 100µL buffer (PBS supplemented with 
2% fetus bovine serum) were stained with ABCB1 PerCP efluor 710 and CD133 PerCP efluor 
710 antibodies (Miltenyi Biotec, Germany) at concentrations suggested by the manufacturer for 
20 min on ice. Cells were washed twice in the buffer and analyzed by LSR II Green flow cytometer 
(BD Biosciences). Respective isotype antibodies conjugated with the same fluorophore were used 
as controls. 
Mitotracker staining: One million cells in 1mL of 10% DMEM medium were incubated for 20 min 
at 370C with 1nM MitotrackerTM Deep Red FM (Life Technologies, Carlsbad, CA) followed by flow 
cytometry analysis using LSR II Green (BD Biosciences).      
8. Western blotting 
Cell lysis was performed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate [SDS]) containing protease inhibitors (1 mM 
phenyl-methyl sulphonyl fluoride, 1 μg/mL aprotinin, 1 μg/mL leupeptin). Cell lysates were 
centrifuged at 15000g for 30 minutes to remove debris, and proteins quantified using Bio-Rad 
DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). Total protein (40 μg/well) was 
fractionated by 10% or 15% SDS–polyacrylamide gel electrophoresis (PAGE). Fractionated 
proteins were electrophoretically transferred onto polyvinylidene difluoride membranes. 
Following transfer, membranes were washed in PBST (phosphate-buffered saline [PBS] and 
0.1% Tween 20) followed by 1 hour blocking in 5% nonfat dry milk in PBST. Blots were incubated 
overnight at 4°C with primary antibodies with respective dilutions (diluted in 2% bovine serum 
albumin in PBS) (Supplementary Table 2). Glyceraldehyde 3-phosphate dehydrogenase and β-
actin were used as loading controls for protein normalization. The membranes were then washed 
in PBST (3 × 10 minutes), probed with the appropriate secondary antibodies (Supplementary 
Table 2), incubated for an hour at room temperature, then washed with PBST (3 × 10 minutes). 




Protein lysates were prepared (900 μg in 750 μL) and incubated overnight with PAF1 (4 μg), 
PHF5A (4 μg), and control immunoglobulin (Ig)-G antibodies (4 μg) (Supplementary Table 3). We 
next added the lysate-antibody mix with protein A/G Sepharose beads (Sigma-Aldrich Corp., St 
Louis, MO), followed by incubation on a rotating platform overnight at 4°C. After incubation, we 
washed the lysate-antibody-bead mix 4 times with lysis buffer. We then resolved 
immunoprecipitates and total cell lysates electrophoretically on SDS-PAGE (15%), followed by 
transferring resolved proteins onto the polyvinyldifluoride membrane. After blocking membranes 
with 5% nonfat dry milk in PBST for at least 1 hour, we added anti-PHF5A primary antibody 
(Supplementary Table 3). Next, we washed immunoblots 5 times (5 × 10 minutes) with PBST, 
followed by incubation for 2 hours with respective secondary antibodies (Supplementary Table 2). 
After washing with PBST 5 times, we performed the reaction with enhanced chemiluminescence 
ECL reagent (Thermo Scientific), and exposed the immunoblots to X-ray film to detect signals. 
10. Immunohistochemistry 
Pancreatic tissues were fixed, embedded in paraffin and sectioned. Immunohistochemistry (IHC) 
was performed as described previously [6]. Briefly, glass slides containing tissue sections were 
baked for 2 hours at 60°C. Tissue sections were deparaffinized using xylene and rehydrated in 
decreasing concentrations of ethanol. The activity of endogenous peroxidase was blocked by 
incubating tissue sections in Bloxall blocking solution (Vector Laboratories, Inc, Burlingame, CA) 
for 10 minutes at room temperature. After peroxidase blocking, antigen retrieval was performed 
by boiling tissue sections in 0.5% citrate buffer for 15 minutes. Next, tissue sections were blocked 
in 2.5% normal horse serum for 1 hour at room temperature. After blocking, sections were 
incubated with primary antibodies overnight at 4°C. Primary antibodies and respective dilutions 
used for IHC are listed in Supplementary Table 3. After overnight incubation with primary 
antibody, tissue sections were washed in PBS and incubated for 1 hour with horseradish 
peroxidase-conjugated secondary antibodies. After washing in PBS, sections were developed for 
colorimetric detection using the 3,3′diaminobenzidine kit (Vector Laboratories, Inc). 
Then, hematoxylin counterstaining was performed followed by dehydration with increasing 
concentrations of ethanol. After dehydration, tissue sections were dried and mounted with 
Permount (Cat. No. 17986-05; Fisher Scientific, Hatfield, PA). 
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Slides containing human pancreatic tissue sections (of the benign pancreas, PDAC without 
smoking history, and PDAC with smoking history) (n = 15) were the kind gifts from Dr. Talmon A. 
Geoffrey (pathologist, University of Nebraska Medical Center [UNMC]). Smoking status and tumor 
grade details of these human tissue sections are listed in Supplementary Table 8. IHC for PAF1 
was performed on these human tissue sections as described previously. For FOSL1 IHC staining 
on these human tissues sections, double stain IHC kit (M&R on human tissue; Abcam, 
Cambridge, MA) was used and performed IHC by following the manufacturer’s instructions. IHC-
stained mice and human tissue sections were scored by Dr. Subodh M. Lele (Pathologist, UNMC), 
and intensity of FOSL1, PAF1, PHF5A, and SOX9 expression was graded on a scale of 0 to 3 
(0, no staining; 1+, weakly positive; 2+, moderately positive; 3+, strongly positive). The 
percentage of FOSL1, PAF1, PHF5A, and SOX9 positive staining in PDAC ducts (Nuclear) was 
scored in a range of (0–100% or 0–1). A histoscore was calculated by multiplying intensity (0–3) 
and positivity (0–1), ranging between 0 and 3. Graph Pad Prism software was used to 
calculate P values and to design graphs. 
Human PDAC tissues of primary, liver metastasis and lung metastasis were obtained from the 
Rapid Autopsy Program of the University of Nebraska Medical Center. IHC for MDR1, ALDH1A1, 
LDH-A, and ATP5B was performed and scored as described above by Dr. Dipak Kumar Prajapati.   
11. Immunofluorescence 
Immunofluorescence analysis on tissue sections was performed as shown previously [6]. Briefly, 
slides containing tissue sections were baked for 2 hours at 60°C. Then tissue sections were 
deparaffinized using xylene, rehydrated with decreasing concentrations of ethanol, and 
permeabilized by incubating in methanol for 30 minutes. After antigen retrieval and blocking in 
5% normal goat serum, sections were incubated with primary antibody overnight at 4°C. After 
washing in PBS, tissue sections were incubated with fluorophore-conjugated secondary antibody 
for 1 hour at room temperature. Primary and secondary antibodies used for immunofluorescence 
and respective antibody dilutions are listed in Supplementary Table 3. Slides were washed in PBS 




12. Nile red staining 
For AF on tissues, Nile red was used to visualize/track lipid content (lipid droplets) and to 
distinguish riboflavin-derived AF from lipid (Lipofuscin)-derived AF. After deparaffinization 
and rehydration, tissue sections were incubated with Bloxall blocking solution (Vector 
Laboratories, Inc) for 10 minutes at room temperature to block peroxidase 
and phosphatase activities, which are the sources of background AF. After washing in PBS, tissue 
sections were then incubated with Nile red (Invitrogen) at dilutions of 1:10,000 for 30 minutes at 
37°C. Tissue sections were washed in PBS and mounted with Vectashield containing DAPI. AF 
was captured using Carl Zeiss imager. 
For AF on cells, we seeded cells on coverslips, fixed with 100% ice-cold methanol for 5 minutes 
at −20°C, followed by washing with PBST 3 times (3 × 5 minutes) and PBS (1 × 5 minutes). After 
blocking in 5% normal goat serum for 1 hour at room temperature, cells were incubated with the 
anti-ABCG2 antibody (1:200) overnight. Next, we washed with PBS (3 × 5 minutes) followed by 
incubation with anti-mouse Alexa Fluor-568 secondary antibody. After washing, we mounted 
coverslips in DAPI medium (DAPI fluoromount-G; Southern Biotech, Birmingham, AL). AF was 
captured using Carl Zeiss Confocal Microscope using 488-nm blue laser. 
For immunofluorescence on spheres, 10-day-old spheres were transferred from low-attachment 
plate to chamber slide and were allowed to attach by incubating at 37°C and 5% Co2 for 12 hours. 
Immunofluorescence staining was performed for Oct3/4 on attached spheres using normal 
immunofluorescence procedure as described previously for cells. Oct3/4 staining and AF (green) 
were captured using Carl Zeiss Confocal Microscope. 
13. Whole transcriptome analysis 
Whole transcriptome analysis (RNA sequencing) was performed on chronic CSE-exposed and 
control cells at the Functional Genomics Core Facility at the City of Hope National Medical Center 
(Duarte, CA). The RNA quality was checked with an Agilent Bioanalyzer (Agilent Technologies, 
Inc, Santa Clara, CA) and all RNA integrity numbers were 10. Library preparation was achieved 
using Illumina (San Diego, CA) TruSeq RNA Sample Preparation Kit according to manufacturer 
protocol. Fifteen cycles of polymerase chain reaction (PCR) amplification were performed for each 
library, followed by an examination of size distribution using an Agilent Bioanalyzer (Agilent 
Technologies, Inc) and a DNA 1000 chip. Each sample used 1 of 12 unique indices (Illumina). All 
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libraries displayed a band between 200 and 500 bp with a peak at approximately 260 bp. 
The Qubit 2.0 Fluorometer (Life Technologies, Inc, Carlsbad, CA) was used to quantitate the 
libraries. Loading was performed at a concentration of 8.6 pM. Sequencing was done on Illumina 
HiScanSQ or HiSeq 2000 Sequencing Systems. 
14. Quantitative real-time PCR 
Total RNA was isolated and complementary DNA was synthesized. Primer sequences were 
designed using Primer Quest and Oligo Analyzer (Integrated DNA Technologies, Inc, Coralville, 
IA) tools. The specificity of each primer set to its target gene was confirmed using Primer BLAST. 
The list of primers used in the study are given in Supplementary Table 4. Real-time PCR was 
performed on the Roche 480 Real-Time PCR System (Indianapolis, IN). Reactions were 
performed in triplicate and template controls were run for each assay under the same conditions 
as described previously.7 
15. Small interfering RNA and CRISPR/Cas9-based knockdown/knockout of PAF1 
Twenty-four hours before small interfering RNA (siRNA) transfection, chronic CSE-treated HPNE 
and Capan1 cells were seeded at a density of 0.5 × 106 cells per well in a 6-well plate. 
Commercially available siRNA against human FOSL1 and PAF1 and control siRNA were 
purchased from OriGene (Rockville, MD). Lipofectamine-2000 transfection reagent (Invitrogen) 
was used to transfect siRNA, carefully following manufacturer recommendations. Down-
regulation of proteins of interest was monitored after 48 hours of siRNA transfection by Western 
blot analysis. Knockout of PAF1 in Capan1 cells was also performed, as shown previously, using 
CRISPR/Cas9 system.8 
16. Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (ChIP) assay was performed by washing cells twice with PBS 
followed by crosslinking in PBS containing 1.5 mM EGS (Ethylene Glycol-bis, 
Succinimidysuccinate). After 15 minutes of incubation at room temperature with agitation, cells 
were fixed by adding 0.4% formaldehyde directly to the PBS-EGS followed by incubation for 15 
minutes. Next, to arrest the cross-linking, cells were added with 125 mM glycine solution and 
incubated for 10 minutes at room temperature with agitation. After washing with PBS, cells were 
scraped in 1 mL of cold PBS and were pelleted by centrifugation at 1200g for 10 minutes at 4°C. 
After centrifugation, pellets were suspended in cell lysis buffer and kept on ice for 15 minutes. 
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Cells were pelleted at 1200g for 10 minutes, and nuclei lysed by resuspending in SDS lysis buffer 
followed by incubation on ice for 10 minutes. After sonication and centrifugation, supernatants 
were collected and incubated with phospho-FOSL1 antibody (4 μg) and control IgG antibody (4 
μg) and incubated at 4°C overnight. Next, 30 μL of protein A and protein G agarose beads (Santa 
Cruz, Dallas, TX) were added and incubated for 6 hours, followed by bead collection and washing 
in low-salt buffer, high-salt buffer, lice buffer, and TE buffer, followed by reverse crosslinking in 
NaCl. After the last wash, ChIP DNA was purified using the ChIP DNA Clean & Concentrator kit 
(The Epigenetics, Irvine, CA). The eluted DNA was used for PCR reaction. The binding of 
phospho-FOSL1 to the region −2170 to +514 of the PAF1 gene was analyzed by PCR. PCR 
primers used for ChIP are listed in Supplementary Table 5. After PCR, products were run on 2% 
agarose gel; DNA bands were excised from the gel and purified the DNA using QIAquick gel 
extraction kit (Qiagen, Valencia, CA) followed by sequencing using forward primers. 
Chromatograms of ChIP DNA sequence quality was verified using Finch TV software program 
(Geospiza, Inc, Seattle, WA). 
17. In vivo tumorigenicity assay 
AF+ and AF− cells were sorted using fluorescence-activated cell sorter from chronic CSE-exposed 
HPNE and Capan1 cells. Cells (40,000) were suspended in 500 μL PBS and mixed 
with Matrigel (Fisher Scientific) (1:1 ratio). Cells (4000) in 100 μL were injected subcutaneously 
into the right (AF+) and left (AF−) flanks of 5-week-old athymic nude mice. Four mice were used 
per group and the appearance of tumors was checked by palpitation 2 times a week. Animals 
were sacrificed soon after tumor nodule reached 0.8 cm in diameter. 
18. Quantification and statistical analysis 
Sigma Plot and Graph Pad Prism were used for statistical analysis. Data are presented as the 
mean ± SD and mean ± SEM. Significance was determined using simple Student t-test. The 
details of the statistics of each experiment can be found in the figure legends. 
19. Data and software availability 
Data resources 
The accession number for RNA sequencing data of smoke-treated HPNE and Capan1 cells is 
GSE101726. Original FCS files of flow cytometry experiments are available 
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at http://flowrepository.org and the repository IDs of all these flow cytometry experiments are FR-
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Cigarette smoking is a major risk factor for pancreatic cancer. Aggressive pancreatic tumors 
contain cancer cells with stem cell features. We investigated whether cigarette smoke induces 
stem cell features in pancreatic cancer cells. KrasG12D; Pdx1-Cre mice were exposed to cigarette 
smoke or clean air (controls) for up to 20 weeks; pancreata were collected and analyzed by 
histology, quantitative reverse transcription polymerase chain reaction, and confocal 
immunofluorescence microscopy. HPNE and Capan1 cells were exposed to cigarette smoke 
extract (CSE), nicotine and nicotine-derived carcinogens (NNN or NNK), or clean air (controls) for 
80 days and evaluated for stem cell markers and features using flow cytometry-based 
autofluorescence, sphere formation, and immunoblot assays. Proteins were knocked down in 
cells with small interfering RNAs. We performed RNA sequencing analyses of CSE-exposed cells. 
We used chromatin immunoprecipitation assays to confirm the binding of FOS-like 1, AP-1 
transcription factor subunit (FOSL1) to RNA polymerase II-associated factor (PAF1) promoter. 
We obtained pancreatic ductal adenocarcinoma (PDAC) and matched non-tumor tissues (n = 15) 
and performed immunohistochemical analyses. Chronic exposure of HPNE and Capan1 cells to 
CSE caused them to increase markers of stem cells, including autofluorescence and sphere 
formation, compared with control cells. These cells increased expression of ABCG2, SOX9, and 
PAF1, via cholinergic receptor nicotinic alpha 7 subunit (CHRNA7) signaling to mitogen-activated 
protein kinase 1 and FOSL1. CSE-exposed pancreatic cells with knockdown of PAF1 did not 
show stem cell features. Exposure of cells to NNN and NNK led to increased expression of 
CHRNA7, FOSL1, and PAF1 along with stem cell features. Pancreata from KrasG12D; Pdx1-Cre 
mice exposed to cigarette smoke had increased levels of PAF1 mRNA and protein, compared 
with control mice, as well as increased expression of SOX9. Levels of PAF1 and FOSL1 were 
increased in PDAC tissues, especially those from smokers, compared with non-tumor pancreatic 
tissue. CSE exposure increased expression of PHD-finger protein 5A, a pluripotent transcription 
factor and its interaction with PAF1. Exposure to cigarette smoke activates stem cell features of 
pancreatic cells, via CHRNA7 signaling and FOSL1 activation of PAF1 expression. Levels of 




Background and rationale 
Pancreatic cancer (PC) is recognized as one of the deadliest diseases [1]. Of various established 
risk factors, cigarette smoking causes 30% of all cases of PC [1], and therefore there is an urgent 
need to develop novel therapeutic strategies to specifically treat patients with PC who have a 
history of smoking. Currently, efforts for the development of such strategies are limited because 
there is no mechanistic understanding of how cigarette smoking is involved in PC initiation and 
progression. 
A previous study from our laboratory showed that cigarette smoke and its major addictive 
component, nicotine, induces progression and metastasis of PC through cholinergic receptor 
nicotinic alpha 7 subunit (CHRNA7)-mediated MUC4up-regulation [2]. Cigarette smoke contains 
more than 4000 chemical components, and among them, nicotine and nicotine-derived 
carcinogens, 4-(methyltyramine)-1-(3-pyridyl)-1-butanone (NNK), N-Nitrosonornicotine (NNN), 
are associated with carcinogenesis [3,4,5]. Recent studies provide evidence for the association 
of cigarette smoke and its ingredients with the enrichment of cancer stemness population in 
various cancers [6,7]. In mice, nicotine promotes initiation and progression of Kras-induced PC 
via Gata6-dependent de-differentiation of acinar cells [8]. In our editorial commentary, we have 
proposed a role for nicotine in pancreatic stemness induction and acinar cell de-differentiation 
[9]. Despite these studies, it still remains uncertain whether and how cigarette smoke induces 
stem cell features in pancreatic cells or PC cells. 
Recent studies have shown that FOS-like 1, AP-1 transcription factor subunit (FOSL1) is 
significantly overexpressed in PC [10]. Loss of FOSL1 reduces stemness properties in 
hepatocellular carcinoma [11]. FOSL1 belongs to the Fos gene family, which consists of 4 
members: FOS, FOSB, FOSL1 (or FRA1), and FOSL2. FOS family members dimerize with 
JUN family proteins, such as c-Jun, JunB, and JunD, forming a dimeric transcription factor 
called Activator Protein-1 (AP-1) transcription factor. FOSL1 transcription factor levels are 
increased in response to a variety of stimuli, including smoking [12]. However, to our knowledge, 
the role of FOSL1 in smoking-induced activation of pancreatic stemness has not been 
investigated before. 
PAF1, human RNA polymerase II-associated factor also known as pancreatic differentiation 
protein 2 (PD2) is a subunit of the PAF1 complex, which is composed of PAF1, Ctr9, Cdc73, Rtf1, 
Ski8, and Leo1, and regulates multiple processes, including transcription initiation and elongation 
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[13,14,15,16]. We and others have demonstrated that PAF1 plays an important role in the 
maintenance of embryonic stem cell (ESC) signature in a complex independent manner. The 
PAF1 maintains pluripotency and self-renewal of mouse ESCs [17, 18]. PHD-finger protein 5A 
(PHF5A) has recently been shown to regulate the self-renewal of ESCs. The endogenous PAF1, 
by interacting with PHF5A activates more than 600 pluripotent genes in ESCs by regulating RNA 
polymerase II elongation in pluripotent loci [19]. We also showed that PAF1 maintains cancer 
stemness population and induces tumorigenesis and metastasis in PC [20, 21]. Overall, these 
studies suggest that PAF1 is a major ESC maintenance factor, and its levels are increased in PC. 
To our knowledge, the role of PAF1 in cigarette smoke-induced PC is unknown. 
In the present study, we sought to determine whether chronic exposure to cigarette smoke and 
its ingredients, nicotine, NNN, and NNK, could enrich pancreatic stemness. We investigated the 
mechanism involved in the smoking-induced promotion of pancreatic stemness and cancer 
stemness population, using in vitro and in vivo models. We observed that chronic exposure to 
cigarette smoke increases PAF1, a major ESC signature protein through CHRNA7/extracellular 
signal-regulated kinase (ERK)/FOSL1/cJun (AP1) signaling pathway. We concluded that chronic 
cigarette smoke exposure promotes pancreatic stemness and that NNN and NNK are the major 
contributing factors for the smoking-induced stemness induction. 
Results 
A. Chronic exposure to cigarette smoking increases stemness in normal pancreatic 
duct cells and PC cells 
To study the effect of cigarette smoking on pancreatic stemness, we prepared CSE using a 
standard protocol in our laboratory [2, 23]. Because nicotine is a major cancer-causing agent 
in cigarette smoke, we first sought to determine the levels of nicotine in CSE. Using liquid 
chromatography-tandem mass spectrometry analysis, we determined the concentration of 
nicotine in CSE to be 33.073 ± 0.698μg/mL (Supplementary Figure 1A, B, and C). 
To determine whether cigarette smoke induces stemness signature in pancreatic duct epithelial 
cells and PC cells, we exposed HPNE and Capan1 cells to CSE (1%) for up to 80 days 
(Figure 1A). Lorenzo et al. [24] recently developed a novel autofluorescence-based technique to 
identify cancer stemness population. The source of AF is riboflavin-loaded intracellular vesicles: 
the riboflavin enters vesicles through ABCG2 transporters using an ATP-dependent process. 
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Because the technique is mainly based on riboflavin, we sought to investigate whether the 
addition of riboflavin increases AF. Flow cytometry analysis of AF showed that the addition of 
riboflavin (30 μM) increased the AF-positive (AF+) population to 0.4% and 1.0% in HPNE and 
Capan1 cells, respectively (Supplementary Figure 2A). We were also interested to observe 
riboflavin-loaded intracellular vesicles with membranous ABCG2 expression using confocal 
microscopy (Supplementary Figure 2B). Confocal microscopy also revealed that CSE significantly 
increases AF+content in HPNE and Capan1 cells (Figure 1B). AF analysis using flow cytometry 
on days 20, 40, and 80 of CSE treatment showed a time-dependent increase in the percentage 
of AF+ cells as compared with respective time point controls (Figure 1C). 
To confirm whether AF+ cells are indeed a stemness population, we sorted AF+ and non-
autofluorescent (AF−) cells using fluorescence activated cell sorting. As expected, AF+ cells show 
elevated expressions of major stemness signature genes, such as Sox2, PAF1, Oct3/4, and 
ABCG2 (Figure 1D). Further, flow cytometry analysis showed more ABCG2+ and 
CD44High population in AF+ cells as compared with AF−cells (Figure 1E). 
Previous studies have shown that the ability to form spheres in vitro is one of the standard ways 
to assess the self-renewal potential of normal and cancer cells [25, 26]. To determine the self-
renewal property of AF+ and AF− populations, we performed the sphere assay and observed that 
AF+ cells showed an increased number of spheres as compared with AF− cells. Besides, AF+ cells 
showed the capacity to form secondary and tertiary spheres (Supplementary Figure 3A). Next, to 
determine in vivo tumorigenicity of AF+ and AF− cells, 4000 cells were injected subcutaneously 
into the left and right flanks of athymic nude mice. AF+ cells sorted from CSE-exposed Capan1 
cells started forming tumor nodules 2 weeks after implantation. After 27 days, mice were 
euthanized and tumors were excised. Compared with AF−cells, AF+ cells sorted from CSE-
induced Capan1 cells showed increased tumor weight (Supplementary Figure 3B). However, the 
AF+ population sorted from CSE-induced HPNE cells could not form tumors even after 4 months 
(Supplementary Figure 3C). 
B. Smoking induces stemness signature in pancreatic ductal epithelial cells and 
cancer cells 
To determine the ability of sphere formation by the CSE-induced whole cell population, we 
performed sphere assay on CSE-exposed HPNE and Capan1 cells on days 20, 40, and 80 of 
CSE exposure. Compared with respective time point controls, CSE-exposed cells showed an 
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increase in the number and size of spheres (Figure 2A). In agreement with this observation, Liu 
and colleagues [23] reported that chronic treatment with CSE increases the number of spheres in 
normal human bronchial epithelial cells. To determine whether cells within the spheres show AF 
and stemness marker expression, we performed immunofluorescence assay for Oct3/4 and AF. 
Cells within spheres formed by CSE-induced HPNE and Capan1 cells showed co-localization of 
AF and Oct3/4 expression (Figure 2B). 
To further investigate the impact of CSE on pancreatic stemness, we analyzed protein 
expression levels of major stemness signature proteins, SOX2, Oct3/4, KLF4, BMI1, Nanog, β-
catenin and PAF1, the pancreatic progenitor cell marker, SOX9, and the cancer stemness 
markers, aldehyde dehydrogenase 1 (ALDH1) and CD44. In HPNE and Capan1 cells, CSE 
markedly induced the expression of stemness signature and cancer stemness markers 
(Figure 2C); however, BMI1 did not show any variation (Supplementary Figure 4A). Of interest, 
CSE induced a more than 3-fold increase in the protein expression levels of PAF1, a master 
regulator of stemness [19] suggesting its importance in smoking-mediated stemness enrichment 
(Figure 2C). To investigate whether commercial CSE (C-CSE) also shows a similar effect on 
stemness marker expressions, HPNE, and Capan1 cells were exposed to 20 μg/mL C-CSE for 
80 days. Increased expression of PAF1 and SOX9 was observed in C-CSE–exposed cells as 
compared with vehicle- (dimethyl sulfoxide) treated control cells (Supplementary Figure 4B). 
Next, we also observed increased expression of ABCG2, SOX9, PAF1, β-catenin, CD44, and 
CD24 in CSE-exposed cells, as revealed by immunofluorescence staining 
(Figure 2D and Supplementary Figure 5A). CSE also significantly up-regulated PAF1 and 
SOX9 messenger RNA (mRNA) levels (Figure 2E). Aldefluor assay [27] showed that CSE 
induces ALDH activity up to 2% in HPNE cells, but up to 50% in Capan1 cells (Supplementary 
Figure 5B). These data suggest that cigarette smoke induces a stemness signature, specifically 
PAF1, in human pancreatic ductal epithelial cells and in PC cells. 
C. Cigarette smoking induces PAF1 in KrasG12D; Pdx-1 Cre mouse 
The findings described previously suggest that cigarette smoke significantly up-regulates PAF1 
in vitro. Previously, we and others showed the importance of PAF1 in the maintenance of 
stemness in ESCs and PC stemness populations [17, 18, and 19] and this triggered us to further 
explore its role in cigarette smoke–enriched stemness in vivo. We observed significantly elevated 
expression of PAF1 in the pancreas of 20 weeks cigarette smoke-exposed control and KrasG12D; 
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Pdx-1Cre mice22 (Figure 3Band C). Of note, PAF1 mRNA levels are also significantly higher in 
cigarette smoke-exposed mouse groups (Figure 3D). We also observed an increased expression 
of SOX9 (Supplementary Figure 6A) and elevated coexpression of PAF1 with CD44 (Figure 3E) 
and SOX9 (Supplementary Figure 6B) in cigarette smoke-exposed mice. Also, cigarette smoke-
exposed pancreas tissues showed an increased AF content as compared with controls 
(Figure 3F). In addition to riboflavin, another source of AF is lipid content or lipofuscin 
[28]. Therefore, we analyzed colocalization of AF and Nile red (lipid content marker) staining in 
the pancreas of cigarette smoke-exposed mice. Results indicated that AF does not emanate from 
lipid content or lipofuscin, and this provides evidence for the purity of riboflavin-derived AF. 
Furthermore, AF is colocalized with PAF1 and ABCG2 (Figure 3G). Colocalization of PAF1 
expression with AF in CSE-exposed HPNE cells is also shown in Supplementary Figure 6B. 
These in vivo data clearly correlated with in vitro findings, suggesting that smoking induces PAF1 
and stemness markers in vivo. 
D. Cigarette smoke induces the enrichment of stemness through PAF1 
Next, we investigated whether up-regulation of the stemness signature in response to cigarette 
smoke exposure is regulated through PAF1. To elucidate this hypothesis, we performed 
CRISPR/Cas9-based knockout (KO) and small interfering RNA–based knockdown (KD) of PAF1 
in Capan1 and HPNE cells, respectively (Figure 4A). We were interested in finding that loss of 
PAF1 reduced protein expression of SOX9 and β-catenin (Figure 4A). Further, silencing of PAF1 
reduced the percentage of cigarette smoke-induced AF cells (Figure 4B and C) and the ABCG2+ 
population (Figure 4D–F) as compared with scramble control. These results suggest that smoking 
induces pancreatic stemness through PAF1. 
E. Smoking-Induced PAF1 is regulated through FOSL1 transcription factor 
To unveil the mechanism involved in the smoking-mediated induction of pancreatic stemness, 
whole transcriptome analysis was performed using RNA sequencing (Gene Expression Omnibus 
database accession number: GSE101726) in CSE-treated HPNE and Capan1 cells 
(Supplementary Figure 7A and B). We found that four stemness-associated genes, including LIF 
(maintains stemness in ESC), ALDH1A3 (cellular detoxifying enzyme and cancer stemness 
marker), ABCC4, ABCG2 (associated with drug resistance), and FOSL1 are commonly 
overexpressed in CSE-exposed HPNE and Capan1 cells. We further validated the precision of 
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our RNA sequencing data by performing quantitative reverse transcriptase polymerase chain 
reaction on these stemness genes (Supplementary Figure 7C). 
We focused on FOSL1, given that it showed up-regulation in both HPNE and Capan1 cells, due 
to its involvement in a variety of cellular events mediated by smoking (Supplementary 
Figure 4A; Supplementary Tables 6 and 7) and to its association with stemness [11]. We thus 
performed PAF1 gene promoter analysis for potential transcription factor binding sites of FOSL1, 
using TRANSFAC software (geneXplain GmbH, Wolfenbüttel, Germany), and observed 10 
FOSL1 binding sites (Supplementary Figure 8). Further, we silenced FOSL1 and observed down-
regulation of cigarette smoking-induced PAF1 in both HPNE and Capan1 cells (Figure 5A). 
However, FOSL1 knockdown did not show any effect on untreated HPNE and Capan1 cells, 
suggesting that FOSL1-mediated PAF1 up-regulation is specific to cigarette smoking (Figure 5A). 
To determine whether cigarette smoke-induced FOSL1 binds to PAF1 promoter, we performed 
chromatin immunoprecipitation (ChIP) assay. ChIP results indicated that FOSL1 specifically 
binds to 3 binding sites (BS9: −2162TGACTGACTGAC−2150; BS1: −67TGAGCAT−61; 
BS3: −836TCACTCAGT−828) among ten predicted binding sites (Figure 5B and Supplementary 
Figure 8). This observation was further confirmed by sequencing of ChIP polymerase chain 
reaction products for these specific sites (Supplementary Figure 9A and B). These results 
indicate that cigarette smoke-induced FOSL1 is involved in the up-regulation of PAF1. 
We also observed the overexpression of FOSL1 (Figure 5C) and its colocalization with PAF1 
(Figure 5C) and CD44 (Supplementary Figure 10) in the pancreas of smoke-exposed control and 
KrasG12D; Pdx-Cre mice. Taken together, accumulating data suggest that smoking-induced 
FOSL1 regulates the PAF1 gene. 
F. PAF1 and FOSL1 co-overexpressed in human pancreatic ductal adenocarcinoma 
To study the relevance of PAF1 and FOSL1 to the human  PDAC, we analyzed the expression of 
FOSL1 and PAF1 in PDAC tissues with smoking history. PAF1 and FOSL1 showed significantly 
increased expression in PDAC tissues as compared with normal pancreas (Figure 5D). Of 
interest, increased expression of PAF1 and FOSL1 was observed in smoker PDAC tissues as 
compared with nonsmoker PDAC (Figure 5D). FOSL1 and PAF1 also showed increased 
colocalization in PDAC tissues of smokers compared with nonsmokers (Figure 5D). 
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G. Smoking induces PAF1 through nACHRα7/ERK/FOSL1-cJUN (AP1) signaling 
pathway 
The observations presented previously indicate that FOSL1 regulates PAF1 under smoking 
treatment. We next investigated the mechanism involved in this process. The up-regulation of 
phospho-FOSL1 (Ser 265) was confirmed in HPNE and Capan1 cells following chronic 
exposure to CSE and C-CSE (Figure 5E and Supplementary Figure 4B). We further examined 
whether CSE would also activate FOSL1 interacting partner (phospho c-Jun, AP-1 family 
member). We found that the expression of phospho c-Jun (Ser 73) is significantly elevated in 
response to CSE treatment, demonstrating that chronic exposure to cigarette smoke induces up-
regulation of the AP1 (FOSL1-c-Jun) transcription factor (Figure 5E). Next, we aimed to study the 
upstream regulators that mediate cigarette smoke-induced AP1 activation by examining Erk1/2, 
known upstream regulators of AP1 [29, 30]. CSE exposure increased the protein levels of 
phospho Erk1/2 (Thr202/Tyr204) (Figure 5E). The inhibition of phosphoErk1/2 abolished cigarette 
smoke-induced phospho--FOSL1, phospho-cJUN, and PAF1 in CSE-exposed cells (Figure 5F). 
These data suggested that cigarette smoke induces Erk1/2 phosphorylation and that the 
subsequent phosphorylation of FOSL1 may lead to direct transcriptional activation of PAF1. 
Our next goal was to find the upstream receptor that activates the ERK1/2-FOSL1 signaling 
pathway. We analyzed the activation of smoking-associated receptors, including 
CHRNA1, CHRNA7, and TLR4 and observed an increased expression only in CHRNA7 in CSE-
exposed cells. (Figure 5E and Supplementary Figure 11A). Furthermore, inhibition and 
knockdown of CHRNA7 resulted in decreased expression of phospho-ERK, phospho-FOSL1, and 
PAF1 in these CSE-exposed cells (Figure 5G and Supplementary Figure 11B). These results 
indicate that smoking induces PAF1 through the CHRNA7/ERK/FOSL1-cJUN (AP1) signaling 
pathway. 
H. Specific cigarette smoke components, Nicotine, NNK, and NNN induce pancreatic 
stemness and PAF1 
To determine the major cigarette smoke components responsible for pancreatic stemness 
induction, we treated HPNE and Capan1 cells with cigarette smoke components, nicotine, NNK, 
and NNN, for 80 days and analyzed for stemness enrichment. Specifically, NNN and NNK 
treatment significantly enriched the AF population (Figure 6A) and significantly increased sphere 
formation (Figure 6B) in HPNE and Capan1 cells. Further, treatment with NNN and NNK 
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increased the protein expression levels of CHRNA7, p-FOSL1, FOSL1, and PAF1, and this effect 
is similar to that observed with CSE treatment (Figure 6C and D). These data suggest that NNK 
and NNN specifically contribute to cigarette smoke-induced pancreatic stemness through the 
PAF1 mechanism. 
I. Smoking induces interaction between PAF1 and PHF5A, an event required for 
stemness enrichment 
Recent evidence shows that PAF1 interacts with PHF5A and that this complex regulates more 
than 600 pluripotent genes in ESCs [19]. PHF5A is a PHD-finger protein required for PAF1 
complex recruitment, complex stabilization, release of RNA polymerase II proximal promoter 
pause, serine 2 phosphorylation of RNA polymerase II (Ser-2-P-Pol II) and elongation of 
pluripotency gene transcription in ESCs [19,31,32,33]. The PAF1-PHF5A complex-mediated 
activation of pluripotent genes was well studied in ESCs; however, its role in smoking-induced 
enrichment of stemness in PC has not been investigated. Based on this study, we developed a 
hypothesis that PAF1 interacts with PHF5A and regulates the smoking-mediated stemness 
enrichment. Our results showed an increased expression of PHF5A in CSE- and C-CSE-treated 
cells (Figure 7A and Supplementary Figure 4B), as well as in the pancreas of cigarette smoke-
exposed control and KrasG12D; Pdx-Cre mice (Figure 7B and C). A clear co-localization of PAF1 
and PHF5A was also observed by immunofluorescence staining in the pancreas tissues of 
cigarette smoke-exposed mice and CSE-exposed cells (Figure 7B and D and Supplementary 
Figure 12). Also, cigarette smoke increased the interaction between PAF1 and PHF5A compared 
with untreated controls as evidenced by immunoprecipitation assay (Figure 7E). We also 
observed increased protein expression of Ser-2-P-Pol II and Leo1, a PAF1 complex molecule; 
however, other PAF1 complex subunits, including CTR9, CDC73, and SKI8, did not show any 
variation (Figure 7A). Taken together, our data suggest that smoking induces PHF5A and 
increases the interaction between PAF1 and PHF5A, an event required for the activation of 
stemness genes. 
Discussion 
Cigarette smoking is a well-established risk factor for PC; however, a mechanistic understanding 
of PC development in response to cigarette smoking is limited. Accumulating evidence indicates 
that the stemness signature is induced in various cancers that initiate and aggravates tumors [34, 
35]. However, whether and how cigarette smoking induces pancreatic stemness is unknown. 
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Here, we establish for the first time a novel PAF1-mediated mechanism of cigarette smoke-
induced pancreatic stemness. 
Despite several studies showing an association between cigarette smoking and stemness 
induction in various cancers [36, 37], it remains unclear whether exposure to cigarette 
smoke induces stemness in PC. To explore this critical gap in understanding, we 
performed chronic exposure to cigarette smoke in pancreatic normal and cancer cells and found 
that cigarette smoking increases pancreatic stemness. Cigarette smoke exposure increased the 
pancreas-specific multipotent stemness factor, SOX9, and the stemness markers, ALDH1, and 
CD44 in pancreatic normal and cancer cells, suggesting that exposure to cigarette smoke induces 
multipotent stemness fraction and cancer stemness in the pancreas. 
Cigarette smoke-exposed pancreatic normal and cancer cells also showed SOX2, Oct3/4, Nanog, 
and KLF4 expression along with significant overexpression of PAF1, an ESC signature 
maintenance factor, suggesting that cigarette smoking augments an ESC-like stemness program. 
We further found that cigarette smoke-induced stemness signatures in normal cells are almost 
similar to those of PC cells. However, the cigarette smoke-induced stemness population of 
normal pancreatic duct cells did not show any oncogenic potential. Cigarette smoke-induced 
stemness population isolated from normal duct cells failed to form subcutaneous tumors, whereas 
the stemness population of cigarette smoke-induced cancer cells did produce tumors. These data 
suggest that the observed stemness induction under cigarette smoke stress in normal duct cells 
is an early step toward cancerous reprogramming. Consistent with this observation, a recent 
report indicated that airway basal cells of healthy smokers acquire an ESC-like phenotype or 
signature, itself an early step toward malignant transformation [38].  
Our data suggest the possibility that cigarette smoking expands the stemness population in 
normal tissues, and that this mechanism may be responsible for PC initiation. There are two 
possibilities for the expansion of stemness population in response to cigarette smoke exposure. 
First, a cigarette smoke-induced increase in stemness may be due to the promotion of an existing 
stemness population within normal pancreatic tissues. Second, a benign and differentiated cell 
may also take on the stemness phenotype on chronic exposure to cigarette smoke. In the first 
possibility, long-term, continuous, and rapid cell divisions in the stemness population in response 
to extracellular stress may eventually induce mutations leading to complete malignant 
transformation [39]. Investigation of this possibility by increasing the length and amount of 
cigarette smoke exposure would provide clues to PC initiation caused by cigarette smoke. 
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However, we conclude that cigarette smoking does induce stemness signatures in normal and 
PC cells. 
Previous studies suggested PAF1 as a major stemness signature maintenance factor in ESCs 
and cancer cells [18, 19, 20, and 40]. Observations presented previously also show that PAF1 is 
one of the significantly overexpressed stemness factors under the oncogenic stress of cigarette 
smoke. Based on these, we sought to further explore its mechanistic role in cigarette smoke-
induced stemness. As an important piece of evidence that PAF1 maintains stemness, PAF1 loss 
showed reduced expression levels of stemness markers, SOX9, and β-catenin in normal 
pancreatic cells and PC cells. Further, we also identified overexpression of PAF1 in 20 weeks 
cigarette smoke-exposed normal and KrasG12D; Pdx-Cre mice. Additional evidence that PAF1 is 
associated with stemness is found in the fact that cigarette smoke-induced PAF1 expression 
correlates with the expression of other stemness markers, SOX9 and CD44, in cigarette smoke-
exposed normal and KrasG12D; Pdx-Cre mice. Of note, the loss of PAF1 decreased cigarette 
smoke-induced pancreatic stemness, suggesting that PAF1 is a major regulator of cigarette 
smoke-induced pancreatic stemness. 
Furthermore, elevation of FOSL1, a critical transcription factor, was observed in cigarette smoke-
exposed cells along with other stemness genes, including LIF, ALDH1, and ABCG2. Consistent 
with this finding, cigarette smoke was found to activate the AP1 (FOSL1-cJun) signaling 
pathway to induce epithelial-mesenchymal transition in bladder cancer [30]. The loss of FOSL1 
also down-regulated stemness marker expressions and inhibited sphere formation in 
hepatocellular carcinoma cells, suggesting a role for FOSL1 in the maintenance of stemness 
[11]. We also demonstrated that cigarette smoke increases the expression of the FOSL1 gene 
and that it activates the AP1 transcription factor. Given the association between the FOSL1 
transcription factor and stemness, we investigated whether the cigarette smoke-induced PAF1 
gene is regulated by the FOSL1 transcription factor. We observed 10 FOSL1 binding sites near 
or on the PAF1 gene promoter, suggesting the potential of FOSL1 (AP1) binding on the PAF1 
promoter and FOSL1-mediated regulation of the PAF1 gene. Our data suggest that 
FOSL1 specifically binds to 3 of 10 predicted binding sites: 2 are at the distal 
(−2161TGACTGACTGAC−2150 and −836TCACTCAGT−828) and the other at the proximal promoter 
region (−67TGAGCAT−61) of the PAF1 gene. Of interest, cigarette smoke-exposed cells with 
FOSL1 depletion also displayed reduced expression of PAF1, indicating that cigarette smoke–
activated FOSL1 regulates PAF1. 
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Our data also demonstrated that the pancreas of patients with PDAC shows increased PAF1 and 
FOSL1 expression as compared with healthy persons. Also, PAF1 and FOSL1 expressions are 
higher in the pancreas of patients with PDAC who have a smoking history, suggesting a strong 
correlation of PAF1 and FOSL1 expressions with smoking history in patients with PDAC. 
We also proved that cigarette smoke induces PAF1 through a CHRNA7-ERK1/2-FOSL1 signaling 
pathway. The FOSL1 is a known downstream effector of the ERK pathway [29] and a previous 
study from our laboratory showed that cigarette smoke and its component, nicotine, induces PC 
by activating CHRNA7-ERK1/2-MUC4 pathway [2]. Consistent with these findings, CHRNA7 and 
its downstream effector ERK show up-regulation in response to cigarette smoke treatment. 
Inhibition of CHRNA7 and ERK reduces expression levels of the downstream signaling 
molecules, phospho-FOSL1 and PAF1. Thus, our data suggest that one mechanism by which 
cigarette smoke promotes pancreatic stemness is through the CHRNA7-ERK1/2-FOSL1-PAF1 
signaling pathway. 
We next sought to investigate the cigarette smoke ingredients most responsible for activation of 
the CHRNA7-ERK1/2-FOSL1-PAF1 signaling pathway. We demonstrated that cigarette smoke 
components, specifically NNN and NNK, induce pancreatic stemness, as evidenced by the 
increased percentage of AF and up-regulation of stemness markers, SOX9 and KLF4. Moreover, 
these cigarette smoke components induced signaling molecules of the CHRNA7-ERK1/2-FOSL1-
PAF1 signaling pathway. Overall, NNK and NNN are the major cigarette smoke components that 
are responsible for cigarette smoke-mediated stemness enrichment. 
We further found that cigarette smoke induces PHF5A, a PAF1 complex recruiting and stabilizing 
protein, and increases the interaction between PHF5A and PAF1. A recent study showed that 
PAF1 interacts with PHF5A and that the PAF1-PHF5A complex regulates 686 stemness genes 
in ESCs [19]. Another study demonstrated that pluripotent genes in differentiated somatic 
cells are in an inactive state due to the RNA polymerase II proximal promoter pause [31]. Loss of 
PHF5A in ESCs increased RNA polymerase pausing and reduced Ser-2-P-Pol II levels in the 
promoter regions of PAF1 target or pluripotent genes, thereby reducing the expression of these 
genes [19]. These studies indicate that PHF5A and PAF1 are required for the pause release and 
for maximum levels of Ser-2-P-Pol II at the promoter regions of pluripotent genes. In agreement 
with this, cigarette smoke increased the levels of Ser-2-P-Pol II in pancreatic normal and cancer 
cells. Overall, our observations suggest that cigarette smoking increases the PAF1-PHF5A 
interaction that is required for the activation of stemness genes. 
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Altogether, our results show that cigarette smoke induces the PAF1 gene through the CHRNA7-
ERK-FOSL1 signaling pathway, resulting in the induction of a stemness signature (Figure 7F). 
On induction of PAF1 in response to cigarette smoke, PAF1 interacts with PHF5A and may 
reprogram a differentiated cell or cancer cell population into stemness or a cancer stemness 
population by up-regulating stemness genes; however, this suggestion requires further research. 
However, our study shows for the first time a novel mechanism of cigarette smoke-induced 
expansion of the pancreatic stemness population. In the future, our findings may contribute to the 

















Figure 1. Exposure to cigarette smoke increases pancreatic stemness. (A) HPNE and 
Capan1 cells were exposed to CSE (1%), commercial CSE (C-CSE) (20 μg/mL), or to cigarette 
smoke components, nicotine (2 μM), NNK (2 μM) and NNN (2 μM), for 80 days (2 days exposure 
per passage; thus, up to 40 passages). (B) Confocal imaging for AF in CSE-treated (CSE-T) cells 
compared with untreated controls. AF (green) and nuclei were stained using DAPI (blue) (n = 4). 
Scale bars = 50 μm. (C) Left: Flow cytometry analysis of AF content in CSE-exposed cells at 
different treatment time points. AF cells were excited using a 488-nm blue laser and filters, 530/30 
and 585/42 1 550LP Blue Det A-A. Right: Percentage of AF cells at different time points of CSE 
exposure as compared with respective time point controls. (n = 3). (D) Quantitative reverse 
transcription polymerase chain reaction assays for stemness genes in AF− and AF+ population 
sorted from CSE-exposed cells. Data shown are normalized with β-actin expression (n = 3). (E) 
Left: Flow cytometry analysis for ABCG2+ and CD44High population in AF− and AF+ cells. CSE-
exposed cells were subjected to immunophenotyping using anti-ABCG2-APC or anti-CD44-APC 
antibody. AF+ and AF− populations were selected and analyzed for ABCG2 or CD44 positivity 
using flow cytometer. Right: Percentage of ABCG2+ and CD44Highpopulation in selected AF− and 
AF+ populations of CSE-exposed cells (n = 3). (B–E) Data represent mean ± SD (P values were 
















Figure 2. Cigarette smoke exposure augments pancreatic stemness in vitro. (A) Sphere 
formation assays performed on CSE-exposed and -unexposed HPNE and Capan1 cells; 2000 
cells/well were seeded in 96-well ultra-low attachment plates in stem cell medium. Left: 
Morphology of 10-day-old spheres. Scale bar = 200 μm. Right: Number of spheres per 2000 cells 
at different time points of CSE exposure as compared with respective time point controls. Data 
represent mean ± SD (n = 6). (P values were calculated by Student t test.) ∗P < .05, ∗∗∗P < .001. 
(B) Confocal imaging. Spheres were immunostained for Oct3/4. Confocal images were captured 
for Oct3/4 (red staining), AF (green staining), and DAPI (blue staining for nuclei). Scale bar = 100 
μm. (C) Immunoblotting assays for stemness or cancer stemness markers in untreated and CSE-
treated HPNE and Capan1 cells. β-actin was used as a loading control. (D) Immunofluorescence 
staining on chronically CSE-exposed and -unexposed cells for stemness markers, ABCG2, 
SOX9, and PAF1. Nuclei were stained in blue (DAPI) and red staining indicates ABCG2, SOX9, 
and PAF1 expression. Scale bar = 100 μm. (E) Quantitative reverse transcription polymerase 
chain reaction assay on CSE-exposed and -unexposed HPNE and Capan1 cells for PAF1 and 
SOX9 genes. Data shown are normalized for β-actin expression. Data represent mean ± SD (n = 
3). (P values were calculated by Student t test.) ∗P < .05, ∗∗P < .01 ∗∗∗P < .001. DAPI, 4′,6-

















Figure 3. Cigarette smoke exposure induces PAF1 in vivo. (A) Ten-week-old control and 
KrasG12D Pdx-Cre mice were exposed to cigarette smoke for 20 weeks (3 hours; twice a day) using 
Teague TE-10C system. Filtered air was used to expose control animals. 
(B) Immunohistochemistry staining of PAF1 protein in pancreatic tissues obtained from cigarette 
smoke–exposed (CS-T) control and KrasG12D Pdx-Cre mice. Scale bars = 100 μm. (C) Histo score 
(H score) of PAF1 protein expression. Data represent mean ± SD (n = 6). (P values were 
calculated by Student t test.) ∗∗P < .01. (D) Quantitative reverse transcription polymerase chain 
reaction assay on pancreatic tissues obtained from cigarette smoke–exposed control and 
KrasG12D Pdx-Cre mice for PAF1. Data shown are normalized for β-actin expression. Data 
represent mean ± SD (n = 3). (P values were calculated by Student t test.) ∗P < .05, ∗∗P < .01. (E) 
Immunofluorescence staining for PAF1 (green) and CD44 in cigarette smoke–exposed pancreatic 
tissues. Scale bar = 50 μm. (F) Confocal images of pancreatic tissues obtained from cigarette 
smoke–exposed mice showing the AF (green) and localization of Nile red (lipid droplet staining). 
Scale bar = 50 μm. Enlarged boxed image shows the absence of colocalization of AF with Nile 
red (Lipofuscin). (G) Confocal images of pancreatic tissue collected from cigarette smoke–
exposed floxed mice showing the colocalization of PAF1 with ABCG2 and AF (green). 
Arrowheads point to colocalization of PAF1, ABCG2, and AF. Enlarged boxed image shows the 
















Figure 4. Smoking-mediated induction of pancreatic stemness is regulated by PAF1. 
(A) Immunoblotting assay for PAF1, SOX9, and β-catenin in PAF1 KD HPNE and PAF1 
CRISPR/Cas9 KO Capan1 cells. (B) Flow cytometry analysis of AF cells in CSE-exposed HPNE 
and Capan1 cells transfected with PAF1 small interfering RNA and control siRNA. (C) Percentage 
of AF cells in scramble control and PAF1 KD CSE-exposed cells. Data represent mean ± SD (n = 
3). (P values were calculated by Student t test.) ∗P < .05, ∗∗P < .01. (D and E) Flow cytometry 
analysis for ABCG2+ population in scramble control and PAF1 KD CSE-exposed HPNE and 
Capan1 cells. (F) Percentage of ABCG2+ population in scramble control and PAF1 KD CSE-
exposed cells (n = 3). Data represent mean ± SD (n = 3). (P values were calculated by 






















Figure 5. Smoking induces PAF1 through the nACHRα7-ERK1/2-FOSL1/cJun 
(AP1) signaling pathway. (A) Small interfering RNA knockdown of FOSL1. Western blot 
analysis showing FOSL1 knockdown and its effect on PAF1 in CSE-treated and -untreated HPNE 
and Capan1 cells. Glyceraldehyde 3-phosphate dehydrogenase(GAPDH) was used as loading 
control. (B) ChIP assays were performed using chromatin from CSE-exposed cells and the control 
immunoglobulin (Ig) G or phospho-FOSL1 antibodies. Phospho-FOSL1 enriched DNA was used 
in polymerase chain reaction (PCR) assay using primers specific to FOSL1 or AP1 binding sites 
(see Supplementary Figure 8) on the promoter region of PAF1 gene. Chip DNA PCR product was 
resolved on 2% agarose gel, and the DNA bands for BS1–9 are shown. (C) Left: Representative 
images of immunohistochemistry for FOSL1 in pancreatic tissues obtained from cigarette smoke–
exposed control and KrasG12D Pdx-Cre mice. Scale bar = 100 μm. Middle: Immunofluorescence 
staining for PAF1 (stained in red) and p-FOSL1 (stained in green) in cigarette smoke–exposed 
control and KrasG12D Pdx-Cre tissues (nuclei were stained with DAPI). Scale bar = 50 μm. Right: 
Bar chart represents the H score of FOSL1 staining. Data represent mean ± SD (n = 6). (P values 
were calculated by Student t test.) ∗P < .05, ∗∗P < .01. (D) Left: Immunohistochemical staining for 
FOSL1 and PAF1 in human PDAC tissues (with and without smoking history) and in normal 
pancreas. Scale bar = 100 μm. Right: Confocal images showing the coexpression of FOSL1 
(stained in red) and PAF1 (stained in green) in these tissues. Scale bar = 100 μm. Nuclei were 
stained in blue using DAPI. Bar charts below show quantification of FOSL1 and PAF1 staining in 
normal pancreas (n = 15), PDAC without (n = 15) and with (n = 15) smoking history. Data 
represent mean ± SD. (P values were calculated by Student t test.) ∗∗∗P < .001. 
(E) Immunoblotting assays for CHRNA7, p-ERK1/2, ERK1/2, p-FOSL1, FOSL1, p-cJun and 
cJun signaling molecules in CSE-treated cells as compared with untreated controls. (F) 
Immunoblotting assays for p-ERK1/2, ERK1/2, p-FOSL1, FOSL1, PAF1 in CSE-exposed HPNE 
and Capan1 cells with or without ERK1/2 inhibition using PD98059. (G) Small interfering RNA 
knockdown of nACHRα7 in CSE-treated cells. Western blot analysis showing the effect of 










Figure 6. Cigarette smoke components, nicotine, NNN, and NNK are highly responsible for 
augmentation of pancreatic stemness. HPNE and Capan1 cells were left untreated or treated 
with nicotine (2 μM), NNK (2 μM), and NNN (2 μM) for 80 days. (A) Left: Flow cytometry analysis 
of AF content. Right: Percentage of AF+ population in HPNE and Capan1 cells exposed to 
cigarette smoke components as compared with respective controls. Data represent mean ± SD 
(n = 3) (P values were calculated by Student t test.) ∗P< .05, ∗∗P < .01. (B) Sphere formation assay 
was performed on HPNE and Capan1 cells exposed to cigarette smoke components; 2000 
cells/well were seeded in 96-well ultra-low attachment plates in stem cell medium. Left: 
Morphology of 10-day-old spheres. Scale bar = 200μm. Right: Number of spheres per 2000 cells 
in HPNE and Capan1 cells exposed to cigarette smoke components as compared with untreated 
controls. Data represent mean ± SD (n = 6). (P values were calculated by Student t test.) ∗∗∗P < 
.001. (C, D) Immunoblotting assay for CHRNA7, p-FOSL1, PAF1, KLF4, and SOX9. β-actin was 




















Figure 7. Cigarette smoke exposure increases PHF5A and augments interaction between 
PAF1 and PHF5A. (A) HPNE and Capan1 cells were left untreated or treated with CSE (1%) for 
80 days. Immunoblot analysis showing the protein expression levels of PAF1 complex (PAF1C) 
molecules along with serine 2 phosphorylated RNA polymerase II (S2-Phos RNA Pol II) and 
PHF5A. β-actin was used as loading control. (B) Left: Representative images 
of immunohistochemistry for PHF5A in pancreatic tissues obtained from 20 weeks cigarette 
smoke–exposed control and KrasG12D Pdx-Cre mice. Scale bar = 100 μm. Right: 
Immunofluorescence staining for PAF1 (stained in red) and PHF5A (stained in green) in pancreas 
of cigarette smoke–exposed control and KrasG12DPdx-Cre mice models (nuclei were stained with 
DAPI). Scale bar = 50 μm. Bar chart below (C) represents the H score of PHF5A staining in the 
pancreas of cigarette smoke–exposed mice. Data represent mean ± SD (n = 6). (P values were 
calculated by Student t-test.) ∗P < .05, ∗∗P < .01. (D) Immunofluorescence staining for PAF1 and 
PHF5A on HPNE and Capan1 cells exposed to CSE. Coexpression of PAF1 with PHF5A is 
shown. Nuclei were stained with DAPI. (E) Immunoblots showing that PAF1 interacts with PHF5A 
in untreated and CSE-treated HPNE and Capan1 cells. Pull down was performed using PAF1 
antibody, and immunoprecipitates were probed with PHF5A antibody. Immunoglobulin (Ig)G 
control and input, 10% of total lysate, were used as negative and positive controls, respectively. 
(F) Schematic showing overall mechanism involved in the cigarette smoke–mediated induction of 
pancreatic stemness. Exposure of human pancreatic ductal cells and cancer cells to cigarette 
smoke and its components induces stemness by increasing PAF1 through CHRNA7-ERK1/2-
AP1 (FOSL1-cJUN) signaling pathway. Cigarette smoke–induced PAF1 and PHF5A interacts and 













Supplementary figure legends 
Supplementary Figure 1. LC-MS/MS analysis of Nicotine in CSE. (A) Flow diagram showing 
steps followed for LC-MS/MS analysis of Nicotine concentration in 100% CSE. (B) Calibration 
curve standards and linear regression lines for analysis of nicotine standard solution that were 
used for calculating its concentration in 100% CSE. Nicotine concentration in 100% CSE was 
calculated by data calibration and interpolation analysis. Table below shows mean nicotine (m/z 
163.2/132.1) peak areas of nicotine calibration standard samples and unknown 100% CSE test 
sample and their normalized mean values (Peak area of analyte/IS peak area) (n=3). (p values 
were calculated by Student's t test). ∗∗∗p < 0.001. (C) LC-MS/MS MRM chromatograms of nicotine 
and IS in samples: blank (100% methanol), blank with IS, 100% CSE and nicotine calibration 































Supplementary Figure 2. Riboflavin treatment increases AF+ cells. (A) Flow cytometry based 
autofluorescence assay. Flow cytometry plots showing increase in AF+ cells in riboflavin treated 
HPNE and Capan1 cells. HPNE and Capan1 cells were stained with Riboflavin (30µM) for 1hr at 
370C followed by analysis using LSR II Green (BD Biosciences). AF cells were captured using 
488-nm blue laser and best selected as the intersection with filters Blue 530/30-A and 585/42 1 
550LP Blue Det A-A. (B) Representative confocal image showing ABCG2 expression (red 
staining) in membrane of riboflavin (Green staining)-loaded intracellular vesicle. 80 days CSE 
treated HPNE cells were stained with mouse anti-ABCG2 antibody followed by staining with 























Supplementary Figure 3. (A) Sphere formation by AF+ and AF- population. Left: AF- and 
AF+ cells were sorted from chronic CSE exposed HPNE and Capan1 cells, and seeded (2000 
cells/well) in stem cell medium in ultra-low attachment 96 well plate. Pancospheres (formed by 
CSE exposed HPNE) and tumor spheres (formed by CSE exposed Capan1 cells) were imaged 
10 days post-seeding. Primary or secondary spheres were dissociated using enzymatic (Trypsin 
EDTA) and mechanical (using pipette) methods followed by re-seeding for secondary or tertiary 
sphere formation. Right: Bar graph showing the number of spheres per total number of cells 
seeded. Data represent mean ± SD (n=6). (p values were calculated by Student's t test). ∗∗∗p < 
0.001. (B) In vivo tumorigenicity assay. Left: AF+ and AF- cells were sorted using 
Fluorescence activated cell sorter (FACS) from HPNE and Capan1 cells exposed to CSE, and 
4,000 cells in 100µl were injected subcutaneously into the right (AF+) and left (AF-) flanks of 
athymic nude mice. Animals were sacrificed when tumor nodules reached 0.8 cm diameter. 
Right: Bar graph showing the tumor weights. Data represent mean ± SD (n=4). (p values were 






















Supplementary Figure 4. (A) Immunoblot analysis of stemness marker (BMI1) expression 
in HPNE and Capan1 cells exposed to CSE (1%) for 80 days. β-actin was used as a loading 
control. (B) Exposure to commercial CSE (C-CSE) (purchased from Murthy 
Pharmaceuticals) for 80 days increases stemness or cancer stemness markers. HPNE and 
Capan1 cells were exposed to 20µg/mL C-CSE or equal volume of DMSO (vehicle) for 80 days 
as shown in Figure 1A, and analyzed for protein levels of stemness markers, PAF1/PD2 and 
SOX9 along with p-FOSL1 and total FOSL1 (t-FOSL1) signaling protein. β-actin was used as a 



























Supplementary Figure 5. Chronic CSE exposure elevates stem cell marker protein 
expressions and induces aldehyde dehydrogenase (ALDH) activity. (A) Immunofluorescent 
staining of β-catenin, CD44, ALDH1 and CD24 (red staining). Nuclei were counterstained with 
DAPI. Scale bar, 100µm. (B) Representative flow cytometry plots of ALDEFLUOR assay in 80 
days CSE exposed and unexposed HPNE and Capan1 cells. Cells were incubated with 
ALDEFLUOR substrate in the presence and absence of DEAB. A shift in BAAA (activated 
ALDEFLUOR reagent) fluorescence in the absence of DEAB defines the ALDEFLUOR-positive 




















Supplementary Figure 6. Chronic cigarette smoke (CS) exposure induces SOX9 in the 
pancreas of ten-week-old control and KrasG12D Pdx-Cre mice. (A) Left: Immunohistochemistry 
staining of SOX9 protein in pancreatic tissues obtained from 20 weeks CS-exposed (CS-T) control 
and KrasG12D Pdx-Cre mice. Scale bars, 100µm. Bottom: Histo score (H-Score) of SOX9 
expression. Data represent mean ± SD (n=6). (p values were calculated by Student's t test).  ∗p < 
0.05. (B) Immunofluorescence staining for SOX9 (Green) and PAF1/PD2(Red) in CS-exposed 
pancreatic tissues. Boxes within the images are an enlarged sections showing co-expression of 
SOX9 and PAF1/PD2. Scale bar: 50µm. Nuclei were stained with DAPI, 4’,6-diamidino-2-
phenylindole. (C) Immunofluorescence images showing co-localization of PAF1/PD2 expression 
and AF (autofluorescence) in HPNE cells chronically exposed to CSE. Scale bar, 20µm. Nuclei 





















Supplementary Figure 7. Cigarette smoking activates FOSL1 and stem cell genes. (A) Heat 
map, generated from whole transcriptome analysis (RNA sequencing), showing top 50 up and 
down regulated genes in chronic (80 days) CSE exposed HPNE cells (RPKM_10245) as 
compared to HPNE untreated control (RPKM_10244). The log2 RPKM values of differentially 
expressed genes were used to draw the heat map. The RPKM values smaller than 1 
corresponded to scale value of 0 and dark blue. With increasing RPKM values, color progressed 
through blue to red. FPKM values greater than 425 (scale value of 8) shown as red. (B) Heat map 
showing top 100 up- and down-regulated genes in chronic (80 days) CSE exposed Capan1 cells 
(RPKM_10249) compared to untreated control (RPKM_10248). The log2 RPKM values of 
differentially expressed genes were used to draw the heat map. RPKM values smaller than 1 
corresponded to the scale value of 0 and dark blue. With increasing RPKM values, color 
progressed through blue to red. FPKM values greater than 524 (scale value of 8) shown as red. 
(C) Validation of major differentially expressed stem cell genes from RNA sequencing using 
quantitative reverse transcription polymerase chain reaction assay. Data shown are normalized 
for β-actin expression. Data represent mean ± SD (n=3). (p values were calculated by Student's 
















Supplementary Figure 8. Predicted binding sites of phospho-FOSL1 (or AP1) on PAF1 gene 
promoter. 5’ upstream region of PAF1 gene nucleotide sequence was shown. Ten AP1 binding 
sites (BS1 to BS10) were highlighted in red color. Positions of each binding site in relative to TSS 
























Supplementary Figure 9. FOSL1 binds to its consensus binding site (BS) 3 (-
836TCACTCAGT-827) or BS 9 (-2162TGACTGACTGAC-2157) on PAF1 gene promoter. FOSL1 
Chip-enriched DNA was amplified using PCR using primers for BS3 and BS9. Amplified PCR 
product was run on 2% agarose gel, and DNA bands were excised, purified DNA from gel slices 
and performed sequencing. Chromatograms obtained from Chip DNA PCR product sequencing 
and the reference sequence that holds binding sites were shown. Respective binding sites were 






















Supplementary Figure 10. Co-relation of CS induced phospho-FOSL1 (p-FOSL1) expression 
with cancer stemness marker, CD44 in vivo. Control and KrasG12D Pdx-Cre mice were exposed to 
CS for 20 weeks and collected the pancreas tissues. Immunofluorescence staining was 
performed for p-FOSL1 and CD44 on these CS exposed mice pancreas tissues. Nuclei were 



























Supplementary Figure 11. (A) Immunoblotting analysis of CS associated receptors, TLR4 and 
CHRNA1. HPNE and Capan1 cells were left untreated or treated with CSE for 80 days, and 
analyzed for protein levels of TLR4 and CHRNA1. (B) Immunoblotting assay showing that 
inhibition of CHRNA7 receptor with Macamylamine (MAA) reduces the protein levels of phospho-
FOSL1 (p-FOSL1), FOSL1 and PAF1 in chronic CSE exposed HPNE and Capan1 cells. 78 days 
CSE exposed cells were treated with MAA (200 µM) for 24hr (during 40th passage) followed by 






























Supplementary Figure 12. (A) Confocal images showing the expression of PAF1 and PHF5A in 
chronic CSE treated HPNE and Capan1 cells. The co-localization of PAF1 (Green) and PHF5A 
(Red) was shown. Scale bar, 50µm. Nuclei were stained with DAPI, 4’,6-diamidino-2-

























Supplementary Table 1: Chromatographic gradient program used in LC/MS/MS analysis of 










































Supplementary Table 3: List of antibodies used in this study 
ANTIBODIES  SOURCE  IDENTIFIER/DILUTION 
List of primary antibodies used in Immunofluorescence 
OCT3/4 Santa Cruz Cat# Sc-5279 (Ms) (1:100) 
ABCG2 Santa Cruz Cat# Sc-130933 (Rb) (1:200) 
SOX9 Abcam Cat#ab182579 (Rb) (1:300) 
PAF1 Bethyl Cat# Bethyl-A300-173A (Rb) (1:300) 
CD44 Cell Signaling Technology Cat# CST-5640S (Ms) (1:300) 
Anti human Fra1 Polyclonal Invitrogen Cat#PA5-40361 (Rb) (1:200) 
PAF1 mouse mAB In our lab N/A (Ms) (1:100) 
Phospho FOSL1 Cell Signaling Technology Cat# CST-5841S (Rb) (1:200) 
PHF5A Proteintech Group Cat# 15554-1-AP (Rb) (1:200) 
Non phospho β-CATENIN Cell Signaling Technology Cat# CST-19807P (Rb) (1:300) 
ALDH1/2 Santa Cruz Cat# Sc-50385 (Rb) (1:300) 
CD24 Santa Cruz Cat# Sc-11406 (Rb) (1:300) 
List of secondary antibodies used in Immunofluorescence 
Alexa Fluor 568 goat anti-mouse IgG Life Technologies Cat#A11004 (1:300) 
Alexa Fluor 568 goat anti-rabbit IgG Life Technologies Cat#A11011 (1:300) 
Alexa Fluor 488 goat anti-mouse IgG Life Technologies Cat#A11001 (1:300) 
Alexa Fluor 488 goat anti-rabbit IgG Life Technologies Cat#A11008 (1:300) 
Alexa Fluor 647 goat anti-rabbit IgG Life Technologies Cat#A21245 (1:300) 
List of antibodies used in Immunohistochemistry 
PAF1 mouse mAB In our lab N/A (Ms) (1:100) 
SOX9 Abcam Cat#ab182579 (Rb) (1:200) 
FOSL1 (For human tissues) Invitrogen Cat#PA5-40361 (Rb) (1:200) 
FOSL1 (For mouse tissues) Cell Signaling Technology Cat# CST-5281S (Rb) (1:200) 
PHF5A Proteintech Group Cat# 15554-1-AP (Rb) (1:100) 
List of antibodies used in Immunoprecipitation assay 
PAF1 Bethyl Cat# Bethyl-A300-172A (Rb) (4µg/900µg protein) 
PHF5A Proteintech Group Cat# 15554-1-AP (Rb) (1:500) 
ChromPure IgG 
Jackson Immunoresearch 
Laboratories Cat# 011-000-003 (Rb) (4µg/900µg protein) 
List of antibodies used in Chip assay 
Phospho FOSL1 Cell Signaling Technology Cat# CST-5841S (Rb) 
List of antibodies used in Flow cytometry 
CD338 (ABCG2)-APC, human Miltenyi Biotech Cat#130-105-011 
CD44 APC Human Miltenyi Biotech Cat# 130-098-110 
Mouse IgG1 APC Miltenyi Biotech Cat#130-113-758 
Mouse IgG2b APC Miltenyi Biotech Cat#130-098-890 
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Gene Name (Forward and Reverse primers) Amplicon Size 
FOSL1 F: GGGCCTGTGCTTGAACCTGA 152 
R: TCTCCGCTGCTGCTGCTACTC  
PAF1 F: CTCACAGCATTACAGCAAACC 231 
R: GTCTCTTCTACAGGCAGGAAAT  
SOX9 F: GAGCCGGATCTGAAGAGGGA 151 
R: GCTTGACGTGTGGCTTGTTC  
ABCC4 F: GCGGCTGACGGTTACCCTCTT 189 
R: TCTGATGCCTTATCCCAAAAAGCAGT  
ABCG2 F: GAGCCTACAACTGGCTTAGACTCAA 85 
R: TGATTGTTCGTCCCTGCTTAGAC  
ALDH1A3 F: ATCAACTGCTACAACGCCCT 98 
R: TATTCGGCCAAAGCGTATTC  
LIF F: CAAGAATCAACTGGCACAGC 244 
R: AGTGGGGTTCAGGACCTTCT  
SOX2 F: CAAAAATGGCCATGCAGGT 63 
R: AGTTGGGATCGAACAAAAGCTAT  
Oct3/4 F: GGAAGGAATTGGGAACACAAAGG 71 
R: AACTTCACCTTCCCTCCAACCA  
β-actin (Human) F: GGACATCCGCAAAGACCTGTA 143 
R: GCTCAGGAGGAGCAATGATCT  
PAF1 (Mouse) F: CCAGTTGGAAAACCACGAAC 124 




Supplementary Table 5: List of Chip primers used in this study 
Binding site (BS) (Forward and Reverse) Amplicon Size 
BS 1 F:GCTGCTTAAGGCCAATCACC 84 
 R:AGGACTTCGATCCTGTGC  
BS2 F:ATTCTCCTGCCTCAGCTTCC 101 
 R:AGCCTGGTGAAACCTCGTC  
BS3 F:GGAAGGCAATAGAATATCCTGGTA 197 
 R:AAACCTGAGACTGAGTGAT  
BS4 F:GGAGCAGGAGAAGGAAAGATG 88 
 R:CGACAATGGACAGTGAGTGC  
BS 5-8 F: GCTACTTGGGAGGCCGA 562 
 R: ACCCAGGCTGGACTACAGTG  
BS9 F: ATCAGAGCAACCCTGTGTCC 163 
 R: GCTGTGCCTGGTAAGAAGC  
BS10 F: GACTTCATTTCCCCGAAGG 127 











Supplementary Table 6: Significantly enriched GO terms for genes with higher expression in 
smoke treated HPNE versus untreated HPNE cells. 
   
Category Term Count PValue 
Fold 
Enrichment Benjamini Genes 
GOTERM_BP_FAT 
GO:0043066~negative 


















regulation of cell 
proliferation 6 0.027921 3.44 0.536533491 












differentiation 2 0.04462 43.15 0.629044239 LIF, INHBA 
GOTERM_BP_FAT 
GO:0045931~positive 
regulation of mitotic cell 
cycle 2 0.048579 39.56 0.634462234 CYP1A1, ASNS 
GOTERM_BP_FAT 
GO:0006916~anti-







Supplementary Table 7: Related to Figure 5: Significantly enriched GO terms for genes with 




Supplementary Table 8: Details of smoking status and tumor grade of human pancreatic normal 
and tumor tissue sections. 
Block Designator(s) Smoking Status Diagnosis 
F8 Never Smoker Benign Pancreas 
A12 Former Smoker (QD: 9/29/1961) Benign Pancreas 
A14 Former Smoker (QD: 3/21/1980) Benign Pancreas 
A16-A17 Never Smoker Benign Pancreas 
A1 Never Smoker Benign Pancreas 
C4 Never Smoker Benign Pancreas 
D1-D2 Former Smoker (QD: 8/10/2008) Benign Pancreas 
B3-B4 Never Smoker Benign Pancreas 
C3-C4 Never Smoker Benign Pancreas 
A7-A8 Never Smoker Benign Pancreas 
C8 Never Smoker Benign Pancreas 
A1 Former Smoker (QD: 7/16/1992) Benign Pancreas 
B11-B12 Never Smoker Benign Pancreas 
D5 Never Smoker Benign Pancreas 
B3-B4 Never Smoker Benign Pancreas 
G5 Never Smoker Ductal Adenocarcinoma, WD 
G4 Never Smoker Ductal Adenocarcinoma, PD 
B19 Never Smoker Ductal Adenocarcinoma, WD 
E9-E10 Never Smoker Ductal Adenocarcinoma, MD 
E4-E11, E14 Never Smoker Ductal Adenocarcinoma, MD 
C14-C17 Never Smoker Ductal Adenocarcinoma, MD 
A5-A8 Never Smoker Ductal Adenocarcinoma, MD 
E9, E22-E25 Never Smoker Ductal Adenocarcinoma, WD 
E6-E10 Never Smoker Ductal Adenocarcinoma, PD 
A6-A9, A11-A13 Never Smoker Ductal Adenocarcinoma, WD 
A3-A4, A10-A11, A15-A18 Never Smoker Ductal Adenocarcinoma, WD 
B11-B15 Never Smoker Ductal Adenocarcinoma, MD 
B10-B15 Never Smoker Ductal Adenocarcinoma, PD 
B7-B9 Never Smoker Ductal Adenocarcinoma, MD 
A3, A5-A8 Never Smoker Ductal Adenocarcinoma, WD-MD 
C7-C9, C13, C16-C17 Former Smoker (QD: 2/18/1994) Ductal Adenocarcinoma, PD 
B7-B22 Some Day Smoker (40 pack-years) Ductal Adenocarcinoma, MD 
A8-A9 Former Smoker (QD: 1/1/2013) Ductal Adenocarcinoma, MD 
G9-G13 Former Smoker (QD: 4/27/2014) Ductal Adenocarcinoma, MD 
A5-A6, A8 Former Smoker (QD: 7/2/2014) Ductal Adenocarcinoma, MD 
D3 (Frozen) Former Smoker (QD: 10/6/1954) Ductal Adenocarcinoma, MD 
D7-D10 Former Smoker (QD: 10/9/1989) Ductal Adenocarcinoma, MD-PD 
B5-B6 Former Smoker (QD: Unknown) Ductal Adenocarcinoma, MD 
E7-E8 Former Smoker (QD: 6/4/2005) Ductal Adenocarcinoma, WD 
F5-F6, F14-F17 Former Smoker (QD: 9/21/2015) Ductal Adenocarcinoma, MD 
C5-C9, C11 Former Smoker (QD: 7/1/2013) Ductal Adenocarcinoma, WD 
B10-B13 Former Smoker (QD: 11/8/2013) Ductal Adenocarcinoma, MD 
G4-G9 Former Smoker (QD: 12/6/1970) Ductal Adenocarcinoma, MD 
C7 Former Smoker (32 pack-years) Ductal Adenocarcnoma, MD-PD 




Key resources table  
REAGENT or RESOURCE SOURCE IDENTIFIER 
ANTIBODIES (see Supplementary Table 2 
and 3) and PRIMERS (see Supplementary 
Table 4 and 5) 
This paper N/A 
 
 
Experimental Models: Cell Lines 
hTERT-HPNE cells  Dr. Ouellette (UNMC)  
Capan1 ATCC  ATCC (HTB-79) 
Experimental Models: Animals 
Mouse: LSL-KrasG12D and KrasG12D; Pdx-1cre In house developed N/A 
Critical commercial assays   
ALDEFLUOR assay kit  Stem Cell Technologies Cat #01700 
Bio-Rad DC Protein Assay Kit Bio-Rad Cat # 500-0114 
ECL chemiluminescence kit Thermo Scientific Cat#32209 
Illumina TruSeq RNA Sample Preparation Kit Illumina CAT# RS-122-2001 
Double stain IHC kit: M&R on human tissue  Abcam AB210061 
Bloxall blocking solution  Vector Laboratories, Inc. SP-6000 
Chip DNA Clean & Concentrator kit The Epigenetics Company  CAT# D5205 
Software 
TRANSFAC gene X plain www.genexplain.com 
Sigmaplot Systat Software, Inc. www.sigmaplot.co.uk 
ImageJ NIH https://fiji.sc 
BD FACS Diva BD Biosciences N/A 
Zen Imaging Zeiss https://www.zeiss.com/microscopy/us/pro
ducts/microscope-software/zen-lite.html 
PRISM GRAPHPAD Graphpad https://www.graphpad.com/scientific-
software/prism/ 
Multiquant  AB Sciex https://sciex.com/products/software/multiq
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Finch TV Geospiza, Inc. https://digitalworldbiology.com/FinchTV 
Chemicals & Reagents 
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Metastasis of cancer stem cells in 













Pancreatic tumors contain heterogeneous cancer stem cell populations with metastatic abilities. 
Cellular metabolism governs the stem cell and metastatic features of cancer cells; however, the 
specific stem cell and metabolic features of heterogeneous cancer stem cell populations and their 
role in organ-specific homing and colonization remain poorly understood. Here, we identified 
distinct types of cancer stem cell populations: cells with high aldehyde dehydrogenase (ALDH+) 
activity and those with high multidrug resistance (MDR1+). Specifically, we demonstrate that 
ALDH+ cells are oxidative, while MDR1+ cells display increased aerobic glycolysis (Warburg 
effect). Moreover, the specific metabolic and stem cell features of cancer cells are associated with 
their metastasis to a specific organ. Spontaneous liver tropic cell line and human liver metastases 
show multi-drug resistance and aerobic glycolysis, whereas, spontaneous lung tropic cell line and 















Background and Rationale 
Pancreatic cancer is one of the most intractable malignancies, being the seventh leading cause 
of global cancer-related mortality [1]. Most of the pancreatic cancer patients are diagnosed with 
an advanced tumor and distant metastasis stages, which are difficult to treat by current treatment 
strategies.  
Cancer stem cells (CSCs) in pancreatic cancer play a central role in tumorigenesis, development 
of advanced tumors and metastasis [2, 3]. Pancreatic cancer harbors many CSC populations with 
tumorigenic and metastatic features [2-5]; however, the functional differences between one CSC 
populations to the other are poorly understood.  
Studies in breast and pancreatic cancer indicated that CSC populations differ in their energy 
metabolism and show metabolic heterogeneity [6, 7]. In breast cancer, CSCs exist in two states: 
epithelial CSCs and mesenchymal CSCs. Epithelial breast CSCs show aldehyde dehydrogenase 
activity with oxidative metabolism; however, mesenchymal breast CSCs display CD44+CD24- 
phenotype with glycolytic metabolism [6]. Moreover, CD133+ pancreatic CSCs rely on oxidative 
phosphorylation, while a small percentage of metformin resistant pancreatic CSCs show both 
glycolytic and oxidative (intermediate) metabolism [7]. Gemcitabine is one of the critical 
chemotherapy drug utilized to treat pancreatic cancer. Clones with acquired gemcitabine 
resistance show increased glycolytic metabolism and decreased oxidative phosphorylation as 
compared to gemcitabine sensitive cells [8]. Pancreatic tumors also consist of intrinsic resistant 
clones that are resistant to gemcitabine [9]. These findings raise the interesting question of 
whether the gemcitabine-resistant clones have stem cell features and whether these resistant 
clones are distinct from other CSC sub-clones.  
Multiple studies appreciate the role of CSCs in pancreatic cancer metastasis [2, 10]. Based on 
Stephen Paget’s “Seed” and “Soil” theory, cancer cells from primary tumor shed and travel to 
distant organs, which are welcoming homes in order to form an organ-specific metastasis. This 
hypothesis implies that the metastasis formation relies on the intrinsic features of distinct cancer 
cell types in a heterogeneous tumor and the ability of these cancer cells to interact and colonize 
in the host environment. Recently, several studies provide evidence for the organ-specific 
metastasis of cancer cells [11, 12], may be due to different genomic and metabolic variation. It is 
well known that cells within pancreatic tumors are metabolically heterogeneous. Schild et al., have 
proposed that cancer cells during evolution gain metabolic signature that is compatible with their 
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colonization and survival in a specific organ [13]. Lehuede et al., have also suggested that only 
those metabolically flexible cancer cells can survive in distant organs and form metastasis [14]. 
Based on these studies and owing to the association of CSCs with metastasis, we hypothesize 
that distinct sub-types of CSC populations with sub-type specific metabolic and stem cell features 
migrate to a specific organ.  
Here we identified distinct subsets of CSC populations in human and mice pancreatic tumors. 
These populations include aldehyde dehydrogenase (ALDH) and multi-drug resistant (MDR) 
population. Treatment with the chemotherapeutic drug, gemcitabine further increased MDR 
population by decreasing the ALDH population. We also demonstrated that the ALDH population 
relies on oxidative phosphorylation, whereas MDR population display Warburg effect. Moreover, 
liver tropic cells and human liver metastasis showed MDR stem cell phenotype with intermediate 
metabolism, whereas lung tropic cells and human lung metastasis showed ALDH stem cell 
features with oxidative metabolism 
Results 
A. Aldehyde dehydrogenase and multi-drug resistance identifies distinct sub-types of 
CSC populations in pancreatic cancer     
Previous studies demonstrated ALDH and MDR1 as pancreatic CSC markers. Cells expressing 
either ALDH or MDR1 shows in vivo tumorigenic property involved in tumor progression and 
metastasis [4, 15, 16]. However, it is not clear whether ALDH and MDR1 CSC markers identify 
the same or distinct pancreatic CSC populations. For this, we performed immunofluorescence 
staining using ALDH1A1 and MDR1 antibodies on human pancreatic cancer tissues obtained 
from PDAC patients treated with or without gemcitabine chemotherapy. Treatment with 
gemcitabine induces drug resistance leading to the overexpression of MDR1 [17]. As revealed by 
immunofluorescence staining and confocal imaging, ALDH and MDR1 positive cells were 
identified mostly as distinct non-overlapping cell populations in pancreatic tumors obtained from 
patients without gemcitabine treatment (Figure 1A). However, pancreatic tumors with gemcitabine 
treatment showed the loss of ALDH1A1, but the elevated expression of MDR1 (Figure 1A). 
Besides, pancreatic tumors of KrasG12D; Pdx-1 Cre (KC) mice showed distinct localization of these 
CSC markers (Figure 1A).  
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To further explore stem cell features and functional differences between ALDH and MDR1 
populations, we developed distinct in vitro CSC models by using sphere culture method, which 
was described previously [7]. A gemcitabine-resistant cancer cell line was generated by treating 
Miapaca-2, a non-metastatic pancreatic cancer cell line with an increasing concentration of 
gemcitabine. Miapaca-2 parental cells and gemcitabine-treated Miapaca-2 cells were grown as 
spheres and denoted as “Sph” and “Sph+Gem,” respectively. Miapaca-2 cells grown as adherent 
cultures were considered as non-CSC populations and denoted as “Adh” (Figure 1B). To 
characterize Sph, Sph+Gem and Adh populations, we performed Hoechst-33342 based side 
population assay, a gold standard for identifying drug-resistant CSCs [10]. As assessed by flow 
cytometry, the percentage of side population was significantly elevated in Sph+Gem population 
as compared to Adh and Sph populations (Figure1C and D). Also, the percentage of 
autofluorescence (AF), an intracellular marker for CSCs [18, 19] was increased in Sph+Gem cells 
but lowered in Sph cells (Figure1C and E). Analysis of ALDH population using ALDERED assay 
showed relatively an increased percentage of ALDH+ population in Sph cells than in Sph+Gem 
population (Figure1C and F). Gene expression analysis using qRT-PCR also showed 
overexpression of ALDH1A1 and MDR1 in Sph and Sph+Gem populations, respectively 
(Figure1G). Interestingly, differential expression of other stem cell markers, KLF4 and CD44v9 
were observed in these distinct populations as assessed by qRT-PCR. The expression of KLF4, 
a pluripotent stem cell marker was higher in Sph-derived cells; however, augmented expression 
of CD44v9 was identified in Sph+Gem cells (Figure1G). Moreover, flow cytometry analysis 
showed an increased percentage of CD133+ and MDR1+ population in Sph and Sph+Gem 
populations, respectively (Figure1H and I). Together, these data elucidate the existence of distinct 
subtypes of CSC populations in pancreatic tumors with sub-type specific localization and stem 
cell features. 
B. Distinct sub-types of CSC populations in pancreatic cancer show sub-type specific 
metabolic profiles.   
Previous emerging study demonstrates that the metabolic profile of pancreatic CSCs is 
heterogeneous [7]. Distinct CSC populations in breast tumor display specific metabolic profiles. 
ALDH+ breast CSCs show oxidative phosphorylation, while CD44+CD24- breast CSCs display 
glycolysis [6]. In light of these discoveries, we sought to investigate whether the ALDH+ and 
MDR1+ population display population-specific metabolic features. As shown by 
immunofluorescence staining on pancreatic tumors from human PDAC patients and KC mice, 
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MDR1 positive cells were co-expressed with LDH-A, a major enzyme involved in the conversion 
of pyruvate to lactate (Warburg effect). 
On the other hand, the ALDH+ population co-expressed with ATP5B, a subunit of mitochondrial 
ATP synthase and an essential marker of mitochondria. Interestingly, cells expressing LDH-A did 
not show co-expression with ALDH1A1 suggesting that ALDH+ population do not display Warburg 
effect. To further validate this data functionally, we evaluated the extracellular acidification rate 
(ECAR) and oxygen consumption rate (OCR) using various inhibitors of glycolysis and oxidative 
phosphorylation. Miapaca-2 Sph+Gem cells displayed increased ECAR, glycolysis and glycolytic 
capacity relative to non-CSC and Sph populations (Figure 2B-D). In contrast, Sph+Gem cells 
showed decreased OCR, while Sph population showing elevated maximal respiration, spare 
respiratory capacity and ATP production (Figure 2F-I). Consistent with this data, lactate release 
and glucose consumption were also significantly higher in Sph+Gem cells relative to Sph 
population (Figure 2J and K). We further sought to investigate whether these functional metabolic 
differences between Sph and Sph+gem populations correlate with their metabolic gene 
signatures. QRT-PCR analysis showed an elevated expression of genes associated with aerobic 
glycolysis, PDK1, LDH-A, HIF1α and Myc in Sph+gem cells relative to Sph and non-CSC 
populations suggesting that drug-resistant CSC population rely on aerobic glycolysis (Warburg 
effect) for their energy needs (Figure 2L). The gene expression analysis also showed the lower 
expression of glycolytic genes, GLUT1, HK2 (a rate-limiting glycolytic gene), PGM2 and ENO1, 
and diminished expression of Warburg effect genes suggesting that Sph cells mostly rely on 
oxidative phosphorylation (Figure 2L). Further, to evaluate the metabolic profile in these distinct 
CSC models, we performed targeted liquid-chromatography-tandem mass spectrometry (LC-
MS/MS).  
Consistent with the results above, our metabolomic studies showed an increase in lactate and 
other glycolytic metabolites, such as glucose-6-phosphate (Glc-6-P), glyceraldehyde-3-
phosphate (GA-3-P), dihydroxyacetone-phosphate (DHAP), 2-phosphoglycerate (2PGA) and 
phosphoenolpyruvate (PEP) in Sph+Gem cells relative to Sph and non-CSC populations (Figure 
2M) suggesting that Sph+Gem cells follow the Warburg effect. Interestingly, increased relative 
levels of oxidative metabolites, such as citrate, isocitrate, succinate, and malate were also 
observed in Sph+Gem population (Figure 2N) opposing the Warburg effect, which suggests the 
complete impairment of mitochondrial function when aerobic glycolysis is active. Later studies 
challenged this view and identified that the mitochondrial oxidative phosphorylation is still 
functional in cancer cells undergoing aerobic glycolysis [20, 21]. In agreement with these 
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identifications, our data also suggest that oxidative phosphorylation is still functional in Sph+Gem 
cells, in which aerobic glycolysis is active (Figure 2M and N). Decreased lactate levels in Sph 
cells relative to non-CSCs and Sph+Gem suggest that Sph population is relatively oxidative 
(Figure 2M). Taken together, distinct sub-types of pancreatic CSC populations display specific 
metabolic profiles. 
C. Organ-tropic metastatic pancreatic cancer cells display specific stem cell features  
Our next goal was to investigate whether distinct sub-types of pancreatic CSC populations show 
organ-specific metastatic potential. To investigate the stem cell features of organ-specific 
metastatic cells, we selected Miapaca-2 (a non-metastatic cell line), S2-VP10 (a spontaneous 
lung metastasis pancreatic cancer cell line) and L3.6pL (a spontaneous liver metastatic pancreatic 
cancer cell line).  
As shown by sphere formation assay, lung and liver metastatic cells showed increased sphere 
formation as compared to non-metastatic cells (Figure 3A). Immunofluorescence staining using 
ALDH1A1 and MDR1 antibodies followed by confocal imaging showed that lung-specific 
metastasis cells express ALDH1A1, while liver-specific metastasis cells are MDR1 positive 
(Figure 3A). As shown by flow cytometry, the percentage of PROM1+ (CD133) population is ~27 
fold higher in lung tropic cells as compared to liver tropic and non-metastatic cells (Figure 3B and 
C). In contrast, the percentage of AF+ and ABCB1+ populations are higher in liver tropic cells as 
compared to lung tropic and non-metastatic cells. (Figure 3D-F). Further analysis using qRT-PCR 
showed significant overexpression of ABCB1 and PROM1 in liver tropic and lung tropic cells, 
respectively (Figure 3H and I). These results conclude that different organ-specific metastatic 
cells in pancreatic cancer display specific stem cell features. 
D. Organ-tropic metastatic pancreatic cancer cells show specific metabolic profiles                
Next, we sought to determine the metabolic programs of liver and lung tropic pancreatic cancer 
metastatic cells. Immunofluorescence staining showed that ATP5B was abundantly expressed 
and co-expressed with PROM1 in S2-VP10 lung tropic cells, whereas LDH-A is predominantly 
expressed and co-expressed with ABCB1 in L3.6pL liver tropic cells (Figure 4A). Besides, ECAR, 
glucose uptake, and lactate release were more in liver tropic cells relative to lung tropic and non-
metastatic cells (Figure 4B-D); however, OCR, maximal respiration, spare respiratory capacity, 
and ATP production were higher in lung-tropic cells (Figure 4E-H). Moreover, liver and lung 
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metastatic cells showed decreased glutamine uptake (Figure 4I). This is in agreement with recent 
findings that breast cancer liver-metastasis cells show reduced glutamine metabolism [22], and 
the pyruvate over glutamine replenish TCA cycle intermediates in lung metastasis [23].  
To further confirm the metabolic programs of these organ-tropic cells, we performed LC-MS/MS 
analysis. The levels of lactate and other glycolytic metabolites, such as Glc-6-P, fructose-6-
phosphate (Fru-6-P), fructose-1’6 bisphosphate (Fru-1,6-BP), GA-3-P, DHAP, 2PGA, and PEP 
were higher in liver tropic cells relative to lung tropic and non-metastatic populations (Figure 4J) 
suggesting that liver metastatic cells follow the Warburg effect. We also observed increased 
relative levels of oxidative metabolites (Figure 4K), and this is because mitochondrial respiration 
is still active in cancer cells undergoing aerobic glycolysis [20, 21]. Diminished levels of lactate in 
S2-VP10 lung tropic cells relative to non-metastatic and liver tropic L3.6pL cells suggest that lung 
metastatic cells are relatively oxidative (Figure 4J).  
Next, we sought to determine whether phenotypic metabolic changes in distinct organ tropic 
metastatic cells correlate with their metabolic gene signatures. QRT-PCR analysis showed that 
the messenger RNAs of major Warburg effect determinants, Myc, PDK1, and UCP2 were highly 
expressed in liver metastatic cells, whereas the messenger RNAs of these Warburg genes were 
poorly expressed in lung metastatic cells. Taken together, distinct organ-tropic pancreatic cancer 
cells display specific metabolic profiles. 
E. Human lung and liver metastasis showed specific stem cell and metabolic 
signatures relative to primary pancreatic tumor               
To determine whether lung and liver metastasis show specific stem cell and metabolic profiles, 
we investigated the expression levels of stem cell and metabolic markers using 
immunohistochemistry in human primary pancreatic tumor, lung metastasis, and liver metastasis 
tissues (n=8; Figure 5). Analysis of these tumor sections showed an elevated expression of 
ALDH1A1 and ATP5B expression in lung metastasis compared to liver metastasis and primary 
tumor (Figure 5). In contrast, MDR1 and LDHA expression levels were higher in liver metastasis 




Cancer stem cells (CSCs) are critical players of tumor growth and metastasis in pancreatic cancer 
[2, 3]. Emerging evidence suggests that CSCs in the pancreatic tumor are heterogeneous with 
tumorigenic and metastatic properties [2-5, 24]. Studies in breast and pancreatic cancer indicated 
that CSC populations differ in their energy metabolism and show metabolic heterogeneity [6, 7]. 
However, the existence of distinct CSC subtype populations with specific stem cell and metabolic 
signatures and their role in organ-specific metastasis is poorly understood.  
Here, we show that distinct subtypes of CSC populations exist in primary pancreatic tumor with 
subtype-specific stem cell and metabolic profiles. We found ALDH and MDR1 populations as two 
distinct CSC populations. Gemcitabine treatment has been shown to induce drug resistance and 
MDR1 expression [17]. In agreement with this, tumors derived from pancreatic cancer patients 
who underwent gemcitabine therapy showed decreased ALDH population and increased MDR1 
expression suggesting that ALDH and MDR1 population are two distinct populations.  
Next, we investigated the stemness features of these distinct CSC populations. To further explore 
the heterogeneity of CSCs, we developed in vitro distinct CSC models as shown previously [7]. A 
previous study showed that pancreatic cancer cells enriched in sphere culture conditions show 
increased CD133 or ALDH expression [7].  Based on this, we enriched Miapaca-2 cells in sphere 
culture in order to generate CD133+ or ALDH+ population (Sph). On the other hand, gemcitabine 
resistant pancreatic cancer cells grown as spheres were considered as drug resistant sub-type of 
CSCs (Sph+Gem). Pancreatic cancer cells grown as adherent monolayers (Adh) were regarded 
as the non-CSC population. Cells derived from spheres (Sph) showed CD133 and ALDH 
phenotype, while cells derived from spheres treated with gemcitabine showed multi drug 
resistance properties. Besides, Sph and Sph+Gem cells showed specific stem cell features. Sph 
or CD133+ or ALDH+ cells were positive for KLF4, a pluripotent stem cell marker, whereas 
CD44v9, a CSC marker was higher in Sph+Gem or multidrug resistant cells. Altogether, these 
data suggest the existence of distinct subtypes of CSC populations in pancreatic tumors with sub-
type specific stem cell signatures. 
Recent study showed that the metabolic profile of pancreatic CSCs is heterogeneous [7]. Hence, 
we investigated whether ALDH and MDR1 distinct CSC populations show population-specific 
metabolic signatures. Interestingly, we observed that Sph (ALDH+) population shows an 
increased OCR, while Sph+Gem (MDR1+) population shows elevated ECAR, suggesting that 
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ALDH+ population is oxidative, whereas, MDR1+ population is glycolytic. Besides, cells derived 
from Sph+Gem showed elevated glucose uptake and increased lactate release suggesting that 
Sph+Gem cells are highly glycolytic. Besides, gene expression levels of significant Warburg effect 
genes are higher in Sph+Gem cells as compared to Sph cells. These results agree with a previous 
identification that ALDH+ breast CSCs show oxidative phosphorylation, while CD44+CD24- 
breast CSCs display glycolysis [6]. Also, our results were in agreement with a recent study in 
which pancreatic cancer cells treated with gemcitabine showed glycolytic metabolism [8]. Overall, 
distinct CSC populations in pancreatic cancer show population specific metabolic signatures. 
Tumor heterogeneity is at least in part due to the presence of distinct CSC population that 
differentiate and produce heterogeneous tumor bulk [24]. These CSC populations not only initiate 
and propagate tumor but also involved in metastasis. A study also demonstrated that ALDH+ 
breast CSCs show increased metastatic ability [25]. Drug-resistant and CD133+CXCR4+ 
pancreatic CSCs also show elevated metastatic potential [2, 4].  Several recent studies also 
showed the propensity of different CSCs to metastasize to a specific organ. For instance, CD110+ 
colorectal CSCs prefer to form liver metastasis, while CDCP1+ colorectal CSCs form lung 
metastasis [26]. Based on these studies, we hypothesized that distinct sub-types of pancreatic 
CSC populations show organ-specific metastatic potential. We observed an increased 
percentage of ALDH+ and CD133+ population in spontaneous lung metastatic cells (S2-VP10), 
whereas, an elevated percentage of MDR1+ population in spontaneous liver metastatic cells 
(L3.6pL) relative to non-metastatic cell line, Miapaca-2. These results suggest that lung and liver 
metastasis show ALDH and multidrug resistance properties, respectively.   
Metabolic program of cancer cells in a primary tumor is heterogeneous that dictate their future 
metastatic destination [22]. Metabolic program in a specific metastasizing cancer cell needs to be 
compatible with the metabolic environment of its target organ for proper colonization and 
metastasis formation [13]. The liver environment has increased glycolysis and hypoxia so that the 
upcoming cancer cell required to be glycolytic to colonize and survive in the liver. In contrast, the 
lung is with full of oxygen and oxidative stress, and the lung-colonizing cancer cell must be 
oxidative in order to overcome the oxidative barrier and survive in the lung [13]. In light of these 
clues from previous studies, we sought to determine the metabolic programs of liver and lung 
tropic pancreatic cancer metastatic cells. Interestingly, lung tropic cells showed increased 
oxidative phosphorylation while liver tropic cells showed elevated glycolysis. These results 
conclude that different organ-specific metastatic cells in pancreatic cancer display specific stem 
cell and metabolic features.  
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Moreover, human pancreatic cancer lung metastasis showed elevated expression levels of 
ALDH1A1 and ATP5B suggesting that the lung metastasis of PDAC rely on oxidative 
phosphorylation. On the other hand, human pancreatic cancer liver metastasis displayed higher 
expression levels of MDR1 and LDHA, a Warburg effect enzyme indicating that the liver 
metastasis depends on the Warburg effect (increased aerobic glycolysis). Altogether, our study 
showed that human pancreatic tumors consist of distinct sub-types of CSC populations with sub-
type specific metabolic signatures and organ-specific metastasis potential. Identifying cell types 
that metastasize to a specific organ and revealing their stem cell and metabolic features pave the 
















Figure 1. Distinct sub-types of CSC populations with sub-type specific stem cell features 
in pancreatic cancer. (A) Immunofluorescent staining for ALDH1A1 (green) and MDR1 (red) in 
mouse KrasG12D; Pdx-1 Cre (KC) and human PDAC tissues. The nuclei were stained with DAPI. 
Scale bar, 100µm. (B) Light microscopy images showing Miapaca-2 cells grown in sphere culture 
conditions with or without gemcitabine (3µM). The Miapaca-2 cells grown in adherent culture were 
used as non-CSC control. (C) Percentage of side population (SP), autofluorescence (AF) and 
ALDH+ population as analyzed by flow cytometry in Adh, Sph and Sph+Gem cells. (D-F) 
Representative flow cytometry plots of SP assay (D), AF assay (E) and aldered assay (F). (G) 
RT-QPCR analysis of the stem cell markers, ABCB1, ABCG2, PROM1, KLF4 and CD44v9 in 
cells from adherent culture (Adh), sphere culture (Sph) and sphere culture+gemcitabine 
(Sph+Gem). (H&I) Percentage of ABCB1+ cells (H) and CD133+ cells (I) in Adh, Sph and 
Sph+Gem cells as analyzed by flow cytometry. For all panels, significance determined with t-test. 


















Figure 2. Distinct sub-types of CSC populations show sub-type specific metabolic profiles. 
(A) Immunofluorescent staining for ALDH1A1, MDR1, ATP5B and LDH-A in mouse KC and 
human PDAC tissues. The nuclei were stained with DAPI. Scale bar, 100µm. (B) Extracellular 
acidification rate (ECAR) measurement in Miapaca-2 Adh, Sph and Sph+Gem cells subjected to 
sequential injections of glucose (Glc), oligomycin (O), and 2-deoxyglucose (2DG). (C) ECAR 
simultaneously recorded to Oxygen consumption rate (OCR) as shown in (F). (D) Glycolysis after 
the addition of glucose. (E) Glycolytic capacity, a change in ECAR after the addition of oligomycin 
(O), an inhibitor of mitochondrial phosphorylation. (F) OCR in Miapaca-2 Adh, Sph and Sph+Gem 
cells measured by treating with oligomycin (O), FCCP (F), and antimycin plus rotenone (A+R). 
Maximal respiration (G), spare respiratory capacity (H), and ATP production (I) were measured 
from the data acquired from (F). (J) Lactate release assay. (K) Glucose uptake assay. (L) Heat 
map showing RT-QPCR analysis of energy metabolism (glycolytic and oxidative) genes in Adh, 
Sph and Sph+Gem cells. (n=3); P<0.05. (M&N) Relative metabolite abundance in Adh, Sph and 
Sph+Gem cells. Data are presented as mean total metabolite pools ± s.e.m. (n=3). For all panels, 


















Figure 3. Spontaneous liver and lung tropic metastatic cell lines show organ specific stem 
cell features. (A) Light microscopy images showing sphere formation. Scale bar, 100µm. 
Immunofluorescent staining for PROM1 (green) and ABCB1. The nuclei were stained with DAPI. 
Scale bar, 100µm. (B&C) Representative flow cytometry plots of CD133+ cell analysis (B). (n=3). 
Percentage of CD133+ population as analyzed by flow cytometry in Miapaca-2, S2-VP10 and 
L3.6pL cells (C). (D&F) Representative flow cytometry plots of AF assay (D). (n=3). Percentage 
of AF+ population as analyzed by flow cytometry in Miapaca-2, S2-VP10 and L3.6pL cells (F). 
(E&G) Representative flow cytometry plots of ABCB1+ cell analysis (E). (n=3). Percentage of 
ABCB1+ population as analyzed by flow cytometry in Miapaca-2, S2-VP10 and L3.6pL cells (G). 
(H&I) RT-QPCR analysis of the stem cell markers, ABCB1 and PROM1 in Miapaca-2 (non-
metastatic), S2-VP10 (lung metastatic) and L3.6pL (liver metastatic) cell lines. (n=3). For all 
panels, significance determined with t-test. *p<0.05, **p<0.01, ***p<0.001, ns: non-significant, 
p>0.05. 
 
     
















Figure 4. Spontaneous liver and lung tropic metastatic cell lines show organ specific 
metabolic features.  (A) Immunofluorescent staining for PROM1, ABCB1, LDH-A and ATP5B. 
The nuclei were stained with DAPI. Scale bar, 100µm. (B) ECAR measurement in Miapaca-2, S2-
VP10 and L3.6pL cells subjected to sequential injections of glucose (Glc), oligomycin (O), and 2-
deoxyglucose (2DG). (C) Glucose uptake assay. (D) Lactate release assay. (E) OCR in Miapaca-
2, S2-VP10 and L3.6pL cells measured by treating with oligomycin (O), FCCP (F), and antimycin 
plus rotenone (A+R). Maximal respiration (F), spare respiratory capacity (G), and ATP production 
(H) were measured from the data acquired from (E). (I) Glutamine uptake assay. (J&K) Relative 
metabolite abundance in Miapaca-2, S2-VP10 and L3.6pL cells. Data are presented as mean 
total metabolite pools ± s.e.m. (n=3). (L) Heat map showing RT-QPCR analysis of energy 
metabolism genes in Miapaca-2, S2-VP10 and L3.6pL. (n=3); P<0.05. (M) Percentage of MitoHigh 
and MitoLow population as analyzed by Mitotracker staining followed by flow cytometry analysis. 
For all panels, significance determined with t-test. *p<0.05, **p<0.01, ***p<0.001, ns: non-
significant, p>0.05. 
     
















Figure 5. Human lung and liver metastasis show specific stem cell and metabolic profiles 
relative to primary pancreatic tumors. (A) Representative images of ALDH1A1, ATP5B, MDR1 
and LDHA staining in primary pancreatic tumors, lung metastasis, and liver metastasis are shown. 
(B) Graphs corresponding to the quantification of ALDH1A1, ATP5B, MDR1 and LDHA staining 























Supplementary Table 1: List of antibodies used in this study 
ANTIBODIES  SOURCE  IDENTIFIER/DILUTION 
List of primary antibodies used in Immunofluorescence 
MDR1 Santa Cruz Cat# Sc-55510 (Ms) (1:100) 
ALDH1A1 Cell Signaling Technology Cat# 12035S (Rb) (1:200) 
LDHA Cell Signaling Technology Cat#3582S (Rb) (1:200) 
ATP5B Santa Cruz Cat# Sc55597 (Rb) (1:100) 
Human CD133 VioBright FITC Miltenyi Biotec Cat# 130-113-750 (1:100) 
List of secondary antibodies used in Immunofluorescence 
Alexa Fluor 568 goat anti-mouse IgG Life Technologies Cat#A11004 (1:300) 
Alexa Fluor 568 goat anti-rabbit IgG Life Technologies Cat#A11011 (1:300) 
Alexa Fluor 488 goat anti-mouse IgG Life Technologies Cat#A11001 (1:300) 
Alexa Fluor 488 goat anti-rabbit IgG Life Technologies Cat#A11008 (1:300) 
List of antibodies used in Immunohistochemistry 
MDR1 Santa Cruz Cat# Sc-55510 (Ms) (1:100) 
ALDH1A1 Santa Cruz Cat# Sc374149 (Ms) (1:100) 
LDHA Cell Signaling Technology Cat#3582S (Rb) (1:100) 
ATP5B Santa Cruz Cat# Sc55597 (Rb) (1:100) 
List of antibodies used in Flow cytometry 
Anti-Human ABCB1 PerCP-eFluor 710 eBioscience Ref#46-2439-42 (5µL/test) 
Anti-Human CD133 PerCP-eFluor 710 eBioscience Ref# 46-1338-42 (5µL/test) 
Mouse/IgG2a, kappa PerCP-eFluor 710 Invitrogen  Cat#46-4724-82 (5µL/test) 










Supplementary Table 2: List of human qRT-PCR primers used in this study 







































































































Key resources table  
REAGENT or RESOURCE SOURCE IDENTIFIER 
ANTIBODIES (see Supplementary 
Table 2) and PRIMERS (see 
Supplementary Table 3) 
This chapter (Chapter 5) N/A 
 
 
Experimental Models: Cell Lines 
Miapaca-2  ATCC ATCC CRL-1420 
L3.6pL A gift from Dr. Ouellette 
(UNMC) 
 
S2-VP10 A kind gift from Dr. Ashok K. 
Saluja at Miller School of 
Medicine, University of Miami. 
 
Experimental Models: Animals 
Mouse: KrasG12D; Pdx-1cre In house developed N/A 
Critical commercial assays   
ALDEFLUOR assay kit  Stem Cell Technologies Cat #01700 
Bio-Rad DC Protein Assay Kit Bio-Rad Cat # 500-0114 
ECL chemiluminescence kit Thermo Scientific Cat#32209 
Illumina TruSeq RNA Sample 
Preparation Kit 
Illumina CAT# RS-122-2001 
Bloxall blocking solution  Vector Laboratories, Inc. SP-6000 
Seahorse XF Cell Mito Stress Test Kit Agilent (Seahorse) PART NUMBER: 103015-100 
Seahorse XF Glycolysis Stress Test 
Kit 
Agilent (Seahorse) PART NUMBER: 103020-100 
Glucose Uptake-Glo Assay Promega CAT#J1341 
Lactate-Glo Assay Promega CAT#J5021 
Glutamine/Glutamate-Glo Assay Promega CAT#J8021 
Software   
BD FACS Diva BD Biosciences N/A 
Zen Imaging Zeiss https://www.zeiss.com/microscopy/us/
products/microscope-software/zen-
lite.html 
PRISM GRAPHPAD Graphpad https://www.graphpad.com/scientific-
software/prism/ 
Chemicals & Reagents   
Hoechst 33342 Ana Spec Cat#AS-83218 
Verapamil Sigma V4629-1G 
DAPI, FluoroPure™ grade ThermoFisher Scientific Cat# D21490 
Riboflavin Sigma R9504 
Seahorse XF base medium Agilent Part# 103334-100 
Seahorse XFe96 FluxPak mini Agilent Part#102601-100 
Corning® Ultra-low attachment 
culture dishes 
Corning CLS3262-20EA 
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Pancreatic tumors consist of cancer cells with stem cell features known as “cancer stem 
cells (CSCs)”. Pancreatic CSCs are highly tumorigenic and metastatic [1, 2]. However, it is not 
clear how CSCs are induced, and how these cells are involved in the metastasis process. An 
external factor, cigarette smoking has been shown to induce CSCs in lung and breast cancers [3, 
4]. Also, 30% of pancreatic cancer cases are associated with cigarette smoking. Based on these 
studies, our first goal is to investigate whether and how cigarette smoke induces CSCs in 
pancreatic cancer.  
My second goal primarily explores the metastatic function of CSCs in pancreatic cancer. 
Emerging evidence suggests the existence of distinct types of CSC populations in a 
heterogeneous tumor with type-specific genotypic, phenotypic and functional characteristics [5]. 
For instance, breast tumors consist of two distinct CSC populations such as ALDH+ and 
CD44+CD24-. The study also demonstrated that ALDH+ cells rely on oxidative phosphorylation 
for their energy needs, whereas CD44+CD24- population rely on glycolysis [6]. Recent studies 
also proposed the propensity of a specific cancer cell with specific metabolic profile metastasizes 
to a specific organ. For instance, the liver has a high glycolytic environment, and a metastatic cell 
required to be highly glycolytic to overcome the glycolytic barrier in the liver [7]. Based on these 
studies, our second goal is to investigate whether distinct types of CSC populations with type-
specific stemness and metabolic profiles metastasize to a specific organ.   
First, we observed that cigarette smoke induces cancer cells with stem cell features by 
activating CHRNA7 mediated FOSL1 signaling. Second, I identified distinct sub-types of CSC 
populations with sub-type specific stem cell and metabolic features in pancreatic cancer. I also 
observed that these distinct sub-types of CSC populations with type-specific metabolic profiles 
involved in organ-specific metastasis. 
The summary of all the two projects is described below:      
A. Mechanistic role of cigarette smoking on the induction of pancreatic CSCs 
Smoking induces or aggravates diseases in almost all organ systems. Long term smoking is the 
most established risk factor for many cancers, including pancreatic cancer [8]. In our previous 
studies, we have demonstrated that smoking induces metastasis of pancreatic cancer [9, 10]. 
Also, we also observed that smoke exposure induces the progression of pancreatic cancer from 
pre-neoplastic condition (Pancreatic Intraepithelial lesions-PanINs) [9]; however, these studies 
have not discussed the role and importance of cancer stem cells which is an essential factor for 
progression of the disease. Recently, several studies have demonstrated the significant 
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involvement of CSCs in promoting growth and progression of several lethal malignancies 
including pancreatic cancer [2, 11-13]. We have recently demonstrated that PAF1 is a novel 
molecule for the maintenance of self-renewal and drug-resistance of pancreatic CSCs [13]. More 
recently, it has been shown that smoke induces the enrichment of CSC populations in different 
cancers such as lung, esophageal and breast cancer [14-17]. However, it is not known whether 
and how cigarette smoke induces pancreatic CSCs. Based on the previous studies, we 
hypothesized that cigarette smoking induces CSCs in pancreatic cancer by activating key stem 
cell pathways.  
First, we examined the impact of chronic exposure to cigarette smoke on the induction of 
stemness or CSCs. We found that chronic cigarette smoke exposure induces pancreatic 
stemness or CSCs in vitro and in vivo. Next, we sought to identify the mechanism involved in this 
process. Interestingly, we found that chronic exposure of cigarette smoke induces pancreatic 
CSCs inducing PAF1, a significant stem cell marker via CHRNA7 mediated AP1 signaling.   We 
also identified NNN and NNK as an essential cigarette smoke ingredient that induces CSCs 
through this mechanism. This study demonstrates for the first time a novel mechanism of cigarette 
smoke-induced expansion of the pancreatic CSC population. In the future, our findings may 
contribute to the development of targeted therapy for patients with pancreatic cancer who have a 
smoking history. 
B. Cancer stem cell heterogeneity in pancreatic cancer and their role in organ-
specific metastasis 
Emerging evidence suggests the existence of CSC heterogeneity in pancreatic tumors [5]. 
Identification of distinct subtypes of breast CSCs such as ALDH+ and CD44+CD24- with subtype-
specific metabolic profiles and stem cell features is important evidence for the heterogeneity of 
CSCs [6]. Several recent clues also suggest that CSCs have metastatic abilities [1, 18]. Recent 
studies also proposed the propensity of a specific cancer cell with specific metabolic profile 
metastasizes to a specific organ. For instance, the liver has a high glycolytic environment, and a 
metastatic cell required to be highly glycolytic to overcome the glycolytic barrier in the liver. 
Similarly, the lung has an oxidative environment, and an upcoming metastatic cell must be 
oxyolytic to survive in the lung environment [7]. Based on these previous studies, we hypothesized 
that distinct sub-types of CSC populations with type-specific stem cell and metabolic signatures 




First, we sought to investigate whether distinct subtypes of pancreatic CSC populations exist in 
pancreatic cancer with subtype-specific stem cell features. We found that pancreatic cancer 
consists of distinct CSC populations: ALDH+ CSCs and MDR1+ CSCs. Interestingly, ALDH+ 
population showed oxidative phosphorylation, whereas, MDR1+ population showed elevated 
aerobic glycolysis (Warburg effect). Next, we wanted to see whether distinct subtypes of CSC 
populations are associated with organ-specific metastasis. To our interest, a spontaneous lung 
metastatic (tropic) cells and human lung metastasis showed ALDH phenotype and oxidative 
phosphorylation. In contrast, spontaneous liver tropic cells and human liver metastasis showed 
multidrug resistance phenotype with increased glycolysis (Warburg effect).      
This study demonstrates for the first time the existence of distinct sub-types of pancreatic CSCs 
in pancreatic tumors with sub-type specific metabolic and organ-specific metastasis features. 
Identifying a specific CSC sub-type population that metastasizes to a specific organ and 
understanding their metabolic preferences will be instrumental in developing anti-metastatic 
PDAC therapies based on metabolic and stemness features of CSCs.  
Future Directions 
A. Mechanistic role of cigarette smoking on the induction of pancreatic CSCs 
(i) Does cigarette smoke induce the oncogenic transformation of normal pancreatic 
stem/progenitor cells into cancer stem cells? 
Several studies in the past have demonstrated the propensity of normal adult stem/progenitor 
cells to transform into CSCs. This has been shown in intestinal adenomas using lineage tracing 
experiments. This has also been demonstrated in mammary stem/progenitor cells, where ectopic 
expression of mutated oncogenes resulted in their transformation to malignant phenotype [19]. 
However, the molecular mechanism underlying the malignant transformation of normal stem cells 
to CSCs remains unclear [20, 21]. Interestingly, in our preliminary data, we also found enrichment 
of stem cell population in smoke treated normal epithelial cells (HPNE cells) and PAF1 elevation 
in smoke-exposed normal animal pancreas (Figure 1-3 in Chapter 4). Collectively, these studies 
suggest that CSCs may arise from a normal proliferative progenitor cell via mutations caused by 
several causative agents including smoking. Based on these previous pieces of evidence and our 
preliminary results, we will try to understand the effect of smoking on the malignant transformation 
of normal pancreatic stem/progenitor cells.  
(ii) Does cigarette smoke induce the metabolic reprogramming of pancreatic 
normal/cancer cells into stem cells/cancer stem cells? 
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In our most recent study, we demonstrated that chronic exposure to cigarette smoking 
induces stem cell features in pancreatic cells and PC cells by the upregulation of PAF1 through 
CHRNA7 mediated AP1 signaling [22]. Emerging evidence suggests that perturbed metabolism 
and consequent metabolic reprogramming are the underlying causes of various cancers including 
pancreatic cancer and its metastasis [23-25]. Evidence from a previous study suggests that 
metabolic reprogramming drives the conversion of normal somatic cells into induced pluripotent 
stem (iPC) cells through a metabolic shift [26]. Folmes et al. have also shown that alteration in 
metabolism occurs before pluripotent marker upregulation during the reprogramming of the 
somatic cell into iPS cells [27]. In our preliminary data, we also observed an altered energy 
metabolism in human normal pancreatic cells (Figure 1). Based on these studies, we will 
investigate whether cigarette smoking-induced metabolic reprogramming and deregulated 
metabolic pathways contribute to the emergence of pancreatic CSCs and induce metastasis.          
B. Cancer stem cell heterogeneity in pancreatic cancer and their role in organ-
specific metastasis: 
(i) Does targeting aerobic glycolysis and oxidative phosphorylation in MDR1+ and ALDH+ 
population, respectively attenuate their organ-specific metastasis? 
Our results have shown that pancreatic tumors harbor distinct subtypes of pancreatic CSC 
populations. The results also demonstrated that a specific subtype of the CSC population holds 
specific stem cell and metabolic signature. For instance, ALDH+ population showed increased 
oxidative phosphorylation, whereas, MDR1+ population showed glycolysis. Besides, metastasis 
in specific organ showed specific stem cell and metabolic signatures. For instance, lung and liver 
metastasis showed ALDH+ Oxidativehigh population and MDR1+ Glycolysishigh population, 
respectively. In the future, we will target the metabolic pathway in a specific CSC subtype 
population using specific inhibitors, such as metformin and see if it can inhibit organ-specific 
metastasis.       
(ii) Do exosomes mediate and determine organ-specific metastasis of distinct CSC 
populations?  
Hoshino et al., have shown that exosomes secreted by primary tumor cells expressing unique 
integrins determine organotrophic metastasis by preparing pre-metastatic niche (PMN) in target 
organ [28]. Since distinct subtypes of CSC populations metastasize to a specific organ, it may be 
possible that the exosomes released by a specific CSC subtype population travel to a specific 
organ, where it forms a premetastatic niche for the survival and growth of future up-coming CSCs. 
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Figure 1. Chronic exposure to cigarette smoke increases oxidative phosphorylation in 
normal pancreatic cells. Heat map showing the differential expression of metabolism genes in 
smoke treated HPNE cells as compared to untreated control cells. HPNE cells were exposed to 
cigarette smoke extract (CSE) for 80 days followed by whole transcriptomic analysis using RNA 
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